Aromatase inhibitors. Medical search

Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.

Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.

A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer.

An enzyme that catalyzes the desaturation (aromatization) of the ring A of C19 androgens and converts them to C18 estrogens. In this process, the 19-methyl is removed. This enzyme is membrane-bound, located in the endoplasmic reticulum of estrogen-producing cells of ovaries, placenta, testes, adipose, and brain tissues. Aromatase is encoded by the CYP19 gene, and functions in complex with NADPH-FERRIHEMOPROTEIN REDUCTASE in the cytochrome P-450 system.

Derivatives of the steroid androstane having three double bonds at any site in any of the rings.

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Tumors or cancer of the human BREAST.

A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.

An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.

The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.

Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.

Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.

Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.

Derivatives of the steroid androstane having two double bonds at any site in any of the rings.

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.

Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure.

An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.

Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)

A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.

An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women.

Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males.

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.

Megestrol acetate is a progestogen with actions and uses similar to those of the progestogens in general. It also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia. (From Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)

One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.

The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE.

Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.

Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.

A monoamine oxidase inhibitor with antihypertensive properties.

Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.

A species of baboon in the family CERCOPITHECIDAE with a somewhat different social structure than PAPIO HAMADRYAS. They inhabit several areas in Africa south of the Sahara.

A sudden, temporary sensation of heat predominantly experienced by some women during MENOPAUSE. (Random House Unabridged Dictionary, 2d ed)

Pain in the joint.

A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.

A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.

Discomfort stemming from muscles, LIGAMENTS, tendons, and bones.

The process in developing sex- or gender-specific tissue, organ, or function after SEX DETERMINATION PROCESSES have set the sex of the GONADS. Major areas of sex differentiation occur in the reproductive tract (GENITALIA) and the brain.

A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.

The surgical removal of one or both ovaries.

A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. Note that ENCLOMIPHENE and ZUCLOMIPHENE are the (E) and (Z) isomers of Clomiphene respectively.

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

The gamete-producing glands, OVARY or TESTIS.

One of the ESTROGEN RECEPTORS that has greater affinity for ISOFLAVONES than ESTROGEN RECEPTOR ALPHA does. There is great sequence homology with ER alpha in the DNA-binding domain but not in the ligand binding and hinge domains.

Hormones that stimulate gonadal functions such as GAMETOGENESIS and sex steroid hormone production in the OVARY and the TESTIS. Major gonadotropins are glycoproteins produced primarily by the adenohypophysis (GONADOTROPINS, PITUITARY) and the placenta (CHORIONIC GONADOTROPIN). In some species, pituitary PROLACTIN and PLACENTAL LACTOGEN exert some luteotropic activities.

A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.

A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.

Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.

Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.

Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum.

A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES).

The lack of development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations above the mean age at onset of PUBERTY in a population. Delayed puberty can be classified by defects in the hypothalamic LHRH pulse generator, the PITUITARY GLAND, or the GONADS. These patients will undergo spontaneous but delayed puberty whereas patients with SEXUAL INFANTILISM will not.

FIBROUS DYSPLASIA OF BONE affecting several bones. When melanotic pigmentation (CAFE-AU-LAIT SPOTS) and multiple endocrine hyperfunction are additionally associated it is referred to as Albright syndrome.

Pathological processes involving any part of the UTERUS.

A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)

Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.

A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.

Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.

The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS.

A family of freshwater fish comprising the minnows or CARPS.

The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. (1/981)

Tamoxifen (tam), an anti-breast cancer agent, is metabolized into tam-N-oxide by the hepatic flavin-containing monooxygenase and into N-desmethyl- and 4-hydroxy-tam by cytochrome P-450s (CYPs). Additionally, tam is metabolically activated by hepatic CYP3A, forming a reactive intermediate that binds covalently to proteins. Tam and 4-hydroxyandrostenedione (4-OH-A) are currently used to treat breast cancer, and it has been contemplated that 4-OH-A be given concurrently with tam to contravene potential tumor resistance to tam. Because alterations in tam metabolism may influence its therapeutic efficacy, the effect of 4-OH-A on tam metabolism was examined. Incubation of tam with liver microsomes from phenobarbital-treated rats, in the presence of 4-OH-A (10-100 microM), resulted in marked inhibition of tam-N-demethylation and tam covalent binding and in decreased tam-N-oxide accumulation; however, there was no inhibition of the formation of 4-hydroxy-tam and of 3,4-dihydroxytamoxifen. These findings indicate that 4-OH-A inhibits CYP3A, but not P-450(s) that catalyze tam 4-hydroxylation. The diminished tam-N-oxide accumulation could be due to decreased N-oxide formation and/or due to increased N-oxide reduction. Incubation of tam-N-oxide with liver microsomes containing heat-inactivated flavin-containing monooxygenase demonstrated that 4-OH-A increases the accumulation of tam, possibly by diminishing its P-450-mediated metabolism. Kinetic studies indicate that 4-OH-A is a competitive inhibitor of CYP3A, but not a time-dependent inactivator. Consequently, the concurrent treatment of tam and 4-OH-A may result in increased tam half-life and thus could potentiate the therapeutic efficacy of tam and diminish the potential side effects of tam by inhibiting its covalent binding to proteins and possibly to DNA. (+info)

Inhibitory effects of nitric oxide on the expression and activity of aromatase in human granulosa cells. (2/981)

The aim of the present study was to explore the mechanisms by which nitric oxide (NO) may inhibit aromatase activity of human granulosa cells. Ovarian granulosa-luteal cells, obtained from patients undergoing in-vitro fertilization (IVF) were cultured in the presence of NO-related substances. After 24 h of culture, aromatase activity of the cells was significantly inhibited by treatment with the NO donors, SNAP or NOC12 at > or =10(-4) M in a dose-dependent manner. Treatment with NO catabolites or a peroxynitrite-releasing compound, SIN1, had no significant influence. Treatment with SNAP at 10(-3) M decreased relative aromatase mRNA values by 72% (P<0.05) and intracellular cyclic AMP concentrations by 53% (P<0.01). However, treatment with H89, an inhibitor of protein kinase A, did not inhibit aromatase activity. Since there were no significant effects of NO catabolites or peroxinitrite, the inhibitory action of NO donors on aromatase must be related to NO release. The action of NO is, in part, attributable to the down-regulation of aromatase gene transcription. Although NO decreased intracellular cAMP values, down-regulation of aromatase gene transcription may not be mediated by protein kinase A-dependent mechanisms. (+info)

Evidence of sex reversal in the gonads of chicken embryos after oestrogen treatment as detected by expression of lutropin receptor. (3/981)

In chicken embryos, there is a difference between the sexes in the onset of lutropin receptor mRNA expression in the gonads. The effects of oestrogen on lutropin receptor expression were studied to investigate the mechanism controlling this difference. Lutropin receptor mRNA expression was detected in the ovaries of sesame oil-treated control female embryos on day 12 of incubation, while no expression was found in the testes of the male controls. Oestradiol administration to genetically male embryos before sexual differentiation resulted in gonadal sex reversal which was characterized histologically by the proliferation of cortical cords and the presence of lacunae. Lutropin receptor expression was detected in the feminizing testis on day 12 of incubation. Administration of aromatase inhibitor (CGS 16949 A) to genetically female embryos before sexual differentiation inhibited the formation of cortical cords, although a relatively weak expression of lutropin receptor was detected. These results indicate that early expression of the lutropin receptor is regulated by oestrogen. (+info)

Presence of an aromatase inhibitor, possibly heat shock protein 90, in dominant follicles of cattle. (4/981)

In cattle, it has been suggested that follicular fluid has direct modulatory effects on follicular growth and maturation. In the first part of this study, an in vitro test using aromatase activity of follicular wall fragments as an end point was validated for cattle follicles and was used to test whether follicular fluid (from dominant or non-dominant follicles) modulates aromatase activity. Fluid from dominant follicles at a concentration of 24 or 12% (obtained during the luteal and follicular phases, respectively) significantly inhibited aromatase activity. Inhibitory activity was low or absent in fluid from non-dominant follicles. FSH-stimulated aromatase activity was also reduced by fluid from dominant follicles, but not to a greater extent than in basal conditions. Finally, charcoal-treated fluid from dominant follicles retained its inhibitory activity. In contrast, ovarian venous serum draining a dominant follicle had no activity at the three concentrations tested (6, 12 and 24%). In the second part of the study, identification of the compounds involved in this modulatory activity was attempted using SDS-PAGE. Comparison of the fluorographs from de novo synthesized proteins stored in follicular fluid (inhibitory medium) with those secreted in incubation medium (inactive medium) demonstrated that one protein (90 kDa, pI 5.8) was significantly (P < 0.05) more abundant in fluid from dominant follicles (2.0 +/- 0.09%) than in the culture medium (1.3 +/- 0.1% of the total proteins). This protein had characteristics similar to those of heat shock protein 90 (hsp 90). Therefore, in the final part of the study, the presence of hsp 90 in ovarian cells and follicular fluid was investigated using immunohistochemistry and western blot analysis. After immunohistochemistry, a positive signal was detected mainly in the granulosa cells of larger follicles and to a smaller extent in thecal cells and oocytes. Western blot analysis also demonstrated the presence of hsp 90 in follicular wall fragments and fluid. When blotting was achieved on a sample of follicular fluid resolved by two-dimensional PAGE, the spot detected had a similar location to that at 90 kDa and pI 5.8. Addition of purified hsp 90 to bovine follicles in vitro depressed aromatase activity by altering the K(m) value (and possibly the Vmax value) of the enzyme. It is proposed that hsp 90 is a functional regulator of follicular maturation through its action on aromatase. (+info)

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. (5/981)

Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in post-menopausal women whose disease has progressed despite tamoxifen therapy: anastrozole (ARIMIDEX, Zeneca), letrozole (FEMARA, Novartis) and vorozole (RIVIZOR, Janssen). All belong to the third generation of non-steroidal aromatase inhibitors, and each is superior to previous generations in terms of potency and selectivity. The trials that have been performed compare each agent to megestrol acetate, and letrozole and vorozole to aminoglutethimide. Although the studies are not directly comparable due to differing study designs and patient populations, it has been demonstrated each of these drugs provides single agent, once-daily, oral palliation of hormone-responsive, post-menopausal metastatic breast cancer. Letrozole is clearly more effective than megestrol acetate, and anastrozole and vorozole are possibly so. All three are better tolerated than the progestin, particularly in terms of weight gain. Both letrozole and vorozole are significantly more effective, and better tolerated than aminoglutethimide. Overall, this most recent generation of aromatase inhibitors is a clear improvement on our current standard second-line therapies. In 1999, tamoxifen remains the first choice in the hormonal therapy of breast cancer. Following tamoxifen failure, the optimal second-line hormonal therapy remains undefined, but aminoglutethimide and megestrol acetate are no longer optimal therapy in this setting. The third-generation non-steroidal aromatase inhibitors must now be compared to each other, to the steroidal aromatase inhibitors, to the pure anti-oestrogens, and to tamoxifen. (+info)

Estrogen-inducible, sex-specific expression of brain-derived neurotrophic factor mRNA in a forebrain song control nucleus of the juvenile zebra finch. (6/981)

The expression of brain-derived neurotrophic factor (BDNF) mRNA is increased significantly within the high vocal center (HVc) of male but not female zebra finches from posthatching day 30-35 on. The population of HVc cells expressing BDNF mRNA included 35% of the neurons projecting to the nucleus robustus of the archistriatum (RA). In the RA and in RA-projecting neurons of the lateral portion of the magnocellular nucleus of the anterior neostriatum, BDNF mRNA was expressed at very low levels in both sexes. The BDNF-receptor trkB mRNA was expressed in the RA, in RA-projecting neurons of lateral portion of the magnocellular nucleus of the anterior neostriatum, and in the HVc, except in most of its RA-projecting neurons. Premature stimulation and an inhibitory effect on the normal increase of the BDNF mRNA expression in juvenile males occurred after treatments with 17beta-estradiol and the aromatase inhibitor fadrozole, respectively. The up-regulation of the BDNF expression in the HVc could be a mechanism by which estrogen triggers the differentiation of cells within and connected to the HVc of male zebra finches. (+info)

Mitogenic and antioxidant mechanisms of estradiol action in preovulatory ovine follicles: relevance to luteal function. (7/981)

The objectives of this investigation were to determine the intrafollicular mechanisms and physiological consequences of estradiol actions in preovulatory ovine follicles. Acute suppression of estradiol production in proestrous ewes by an aromatase inhibitor (Arimidex) was associated with follicular lipid peroxidation, testosterone accumulation, and a granulosa cell deficiency (decreased proliferation/increased apoptosis). Estradiol-17beta stimulated granulosa proliferating cell nuclear antigen (PCNA) and protected cells from oxidative (H(2)O(2)) stress-induced apoptosis in vitro; the PCNA, but not the antiapoptotic response, was negated by the transcriptional inhibitor actinomycin D. Thus, it appears that genomic/mitotic and cytoprotective (oxygen-scavenging) modes of estradiol action operate in preovulatory follicles. Luteal (large steroidogenic cell) function was diminished following ovulation induction of estradiol-deficient follicles. It is suggested that inadequate exposure of the preovulatory follicle to estradiol caused the granulosa lutein insufficiency. (+info)

Gonadal stage-dependent effects of gonadal steroids on gonadotropin II secretion in the Atlantic croaker (Micropogonias undulatus). (8/981)

Involvement of gonadal steroids in the control of gonadotropin II (GTH II) (homologous to LH) secretion was investigated in the Atlantic croaker (Micropogonias undulatus) using gonadectomy (Gx) and steroid replacement paradigms. Gonadectomy in males and females during the late gonadal recrudescence phase elicited significant increases in the gonadotropin response to stimulation by an LHRH analog (LHRHa), without altering basal GTH II secretion. Slow-release silicone elastomer implants of testosterone or estradiol significantly inhibited LHRHa-induced GTH II secretion in gonad-intact and Gx males, and in Gx females, whereas 5alpha-dihydrotestosterone, a nonaromatizable androgen, was ineffective. Pretreatment of fish with an aromatase inhibitor, 1,4, 6-androstatrien-3,17-dione, 2 days before the administration of testosterone implants, completely blocked the negative effect of testosterone on LHRHa-induced GTH II secretion in males, but only partially restored it in females. This suggests that the negative feedback of testosterone in males is primarily mediated by its conversion to estradiol at the level of the hypothalamus and/or pituitary gland, while in females the androgen may also exert a direct inhibitory effect on GTH II secretion, probably mediated via an androgen receptor. In addition, estradiol and testosterone exerted positive effects on basal and LHRHa-induced GTH II secretion during the early-recrudescence phase of the gonadal cycle. The steroids switched to a negative effect on LHRHa-induced GTH II secretion once the fish had fully developed gonads, possibly as a mechanism that prevents a precocious surge in GTH II secretion and final gamete maturation until gametogenesis is complete and the environmental conditions are appropriate for spawning. (+info)

As such, AG is an aromatase inhibitor and adrenal steroidogenesis inhibitor, including both an androgen synthesis inhibitor and ... it is described as a much more potent aromatase inhibitor than adrenal steroidogenesis inhibitor. AG can inhibit aromatase by ... The medication was one of the first adrenal steroidogenesis inhibitors as well as the first aromatase inhibitor to be ... It can be used at a dosage of up to 500 mg four times per day (2,000 mg/day). It is used as an aromatase inhibitor to inhibit ...

https://en.wikipedia.org/wiki/Aminoglutethimide

Aromatase inhibitors like exemestane (which forms a permanent and deactivating bond with the aromatase enzyme) and anastrozole ... Avendaño, C.; Menéndez, J. C. (2008). "Aromatase Inhibitors". Medicinal Chemistry of Anticancer Drugs. Elsevier. pp. 65-73. doi ... Lephart, E. D. (1996). "A review of brain aromatase cytochrome P450". Brain Res. Rev. 22 (1): 1-26. doi:10.1016/0165-0173(96) ... A related aromatization process includes dehydroisomerization of methylcyclopentane to benzene: Aromatases are enzymes that ...

https://en.wikipedia.org/wiki/Aromatization

... aromatase, on breast cancer. Brodie managed to get an aromatase inhibitor into a limited clinical trial in breast cancer ... aromatase. They developed several steroidal aromatase inhibitors, she focused on 4-OHA. In 1979, she moved to Maryland, ... She never intended to retire, and collaborated with Vincent Njar on aromatase inhibitors in prostate cancer for the rest of her ... She presented a paper on her aromatase inhibitors at a Rome conference in 1980, which led to collaboration with Charles Coombes ...

https://en.wikipedia.org/wiki/Angela_Hartley_Brodie

Aromatase inhibitors. *Non-selective: Aminoglutethimide. *Testolactone. *Selective: Anastrozole. *Exemestane. *Fadrozole. * ...

https://en.wikipedia.org/wiki/Acolbifene

Aromatase inhibitors. *Non-selective: Aminoglutethimide. *Testolactone. *Selective: Anastrozole. *Exemestane. *Fadrozole. * ... Kuhl, H.; Schneider, H. P. G. (2013). "Progesterone - promoter or inhibitor of breast cancer". Climacteric. 16 Suppl 1: 54-68. ...

https://en.wikipedia.org/wiki/Hormone_replacement_therapy

... and its major active metabolite 5α-DHNET have been found to act as irreversible aromatase inhibitors (Ki = 1.7 ... Mainly CYP3A4 (liver);[1] also 5α-/5β-reductase, 3α-/3β-HSD, and aromatase. ... Norethisterone is a substrate for and is known to be an inhibitor of 5α-reductase, with 4.4% and 20.1% inhibition at 0.1 and 1 ... Norethisterone is a very weak inhibitor of CYP2C9 and CYP3A4 (IC50 = 46 μM and 51 μM, respectively), but these actions require ...

https://en.wikipedia.org/wiki/Norethindrone

Although aromatase inhibitors and antigonadotropins can be considered antiestrogens by some definitions, they are often treated ... Riggins RB, Bouton AH, Liu MC, Clarke R (2005). "Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer". Vitam. ... aromatase inhibitors (AIs) like anastrozole, and antigonadotropins including androgens/anabolic steroids, progestogens, and ... Aromatase inhibitors and antigonadotropins reduce the production of estrogen, while the term "antiestrogen" is often reserved ...

https://en.wikipedia.org/wiki/Antiestrogen

Aromatase inhibitors. *Non-selective: Aminoglutethimide. *Testolactone. *Selective: Anastrozole. *Exemestane. *Fadrozole. * ... PEP is a strong inhibitor of several enzymes, including acid phosphatase, alkaline phosphatase, and hyaluronidase.[37][38][39] ... Cytochrome P450 inhibitors, especially of CYP3A4, can reduce the metabolism of estradiol and thereby increase estradiol levels ... John's wort; in addition, while ritonavir and nelfinavir are known as strong inhibitors, they have an inducing effect in ...

https://en.wikipedia.org/wiki/Polyestradiol_phosphate

Aromatase inhibitors. *First-generation: Aminoglutethimide. *Testolactone. *Second-generation: Fadrozole. *Formestane. *Third- ...

https://en.wikipedia.org/wiki/8,9-Dehydroestrone

Aromatase inhibitors. *Non-selective: Aminoglutethimide. *Testolactone. *Selective: Anastrozole. *Exemestane. *Fadrozole. * ... Aromatase deficiency is ultimately suspected which is involved in the synthesis of estrogen in humans and has therapeutic ... Rochira V, Carani C (October 2009). "Aromatase deficiency in men: a clinical perspective". Nature Reviews. Endocrinology. 5 (10 ... When estrogen levels were raised through the increased activity of the enzyme aromatase in male lab mice, OCD rituals were ...

https://en.wikipedia.org/wiki/Oestrogen

Aromatase inhibitors. *Non-selective: Aminoglutethimide. *Testolactone. *Selective: Anastrozole. *Exemestane. *Fadrozole. * ...

https://en.wikipedia.org/wiki/Estradiol_acetate

Aromatase inhibitors (e.g., anastrozole). *GnRH agonists (e.g., GnRH). Antigonadotropins. *Sex steroid agonists (via negative ... Influence of growth hormone and of inhibitors of the pituitary adrenal system". Cirug., Ginecol. Urol. 9: 289-326.. ... "Treatment of experimental and clinical schistosomiasis with hormonal inhibitors of ovulation". The American Journal of ...

https://en.wikipedia.org/wiki/Paroxypropione

Aromatase inhibitors. *First-generation: Aminoglutethimide. *Testolactone. *Second-generation: Fadrozole. *Formestane. *Third- ...

https://en.wikipedia.org/wiki/LN-1643

Progesterone.[citation needed] Aromatase inhibitors. Adjusted for age and stage the prognosis for breast cancer in males is ...

https://en.wikipedia.org/wiki/Male_breast_cancer

Medications such as aromatase inhibitors have been found to be effective and even in rare cases of gynecomastia from disorders ... Aromatase inhibitors (AIs) such as anastrozole have been used off-label for cases of gynecomastia occurring during puberty but ... 133-. ISBN 978-1-907816-28-4. de Ronde, W., de Jong, F.H. Aromatase inhibitors in men: effects and therapeutic options. Reprod ... 1 April 2008). "Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development". ...

https://en.wikipedia.org/wiki/Gynecomastia

In addition to its activity as an aromatase inhibitor, plomestane has weak androgenic properties. Minamestane Macdonald F (1997 ... January 1998). "Aromatase inhibitors as potential cancer chemopreventives". Cancer Epidemiology, Biomarkers & Prevention. 7 (1 ... irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as ... Lombardi P (June 1995). "The irreversible inhibition of aromatase (oestrogen synthetase) by steroidal compounds". Current ...

https://en.wikipedia.org/wiki/Plomestane

... is an aromatase (CYP19A1) inhibitor. Huuskonen, P; Myllynen, P; Storvik, M; Pasanen, M (2013). "The effects of ...

https://en.wikipedia.org/wiki/Finrozole

Chalcones are also natural aromatase inhibitors. Chalcones are aromatic ketones with two phenyl rings that are also ... "Chalcones are potent inhibitors of aromatase and 17β-hydroxysteroid dehydrogenase activities". Life Sciences. 68 (7): 751-61. ...

https://en.wikipedia.org/wiki/Chalconoid

Reversible inhibitors[edit]. Types of reversible inhibitors[edit]. Reversible inhibitors attach to enzymes with non-covalent ... fraction of the enzyme population bound by inhibitor [. I. ]. [. I. ]. +. K. i. {\displaystyle {\cfrac {{\ce {[I]}}}{[{{\ce {I ... Uses of inhibitors[edit]. Enzyme inhibitors are found in nature and are also designed and produced as part of pharmacology and ... Examples of irreversible inhibitors[edit]. Trypanothione reductase with the lower molecule of an inhibitor bound irreversibly ...

https://en.wikipedia.org/wiki/Enzyme_inhibition

Raman JD, Schlegel PN (February 2002). "Aromatase inhibitors for male infertility". The Journal of Urology. 167 (2 Pt 1): 624-9 ... Estradiol is produced by action of aromatase mainly in the Leydig cells of the mammalian testis, but also by some germ cells ... Ryan KJ (August 1982). "Biochemistry of aromatase: significance to female reproductive physiology". Cancer Research. 42 (8 ... A portion of the androstenedione is converted to testosterone, which in turn undergoes conversion to estradiol by aromatase. In ...

https://en.wikipedia.org/?title=Estradiol

Examples of aromatase inhibitors include anastrozole and letrozole. Evidence for aromatase inhibitors is limited due to the ... Aromatase inhibitors are medications that block the formation of estrogen and have become of interest for researchers who are ... Nawathe A, Patwardhan S, Yates D, Harrison GR, Khan KS (June 2008). "Systematic review of the effects of aromatase inhibitors ... Attar E, Bulun SE (May 2006). "Aromatase inhibitors: the next generation of therapeutics for endometriosis?". Fertility and ...

https://en.wikipedia.org/wiki/Endometriosis

June 1994). "Novel aromatase and 5 alpha-reductase inhibitors". The Journal of Steroid Biochemistry and Molecular Biology. 49 ( ... Unlike other steroidal aromatase inhibitors such as formestane and exemestane, minamestane does not have androgenic properties ... Minamestane (INN (former developmental code name FCE-24,928) is a steroidal aromatase inhibitor which was under development by ... Combs, Donald W (1995). "Review Oncologic, Endocrine & Metabolic: Recent developments in aromatase inhibitors". Expert Opinion ...

https://en.wikipedia.org/wiki/Minamestane

Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the ... Type II aromatase inhibitors such as anastrozole and letrozole, by contrast, are not steroids and work by interfering with the ... Along with other aromatase inhibitors, exemestane is on the World Anti-Doping Agency's list of prohibited substances. Oral ... Like the aromatase inhibitors formestane and atamestane, exemestane is a steroid that is structurally similar to 4- ...

https://en.wikipedia.org/wiki/Exemestane

"Aromatase inhibitors--mechanisms for non-steroidal inhibitors". Breast Cancer Research and Treatment. 30 (1): 43-55. doi: ... but instead has pharmacological activity as a selective aromatase inhibitor similar to the related drug aminoglutethimide and ...

https://en.wikipedia.org/wiki/Rogletimide

"Bicalutamide and third-generation aromatase inhibitors in testotoxicosis". Pediatrics. 126 (3): e728-33. doi:10.1542/peds.2010- ...

https://en.wikipedia.org/wiki/Comparison_of_bicalutamide_with_other_antiandrogens

"Bicalutamide and third-generation aromatase inhibitors in testotoxicosis". Pediatrics. 126 (3): e728-33. doi:10.1542/peds.2010- ... As such, its levels in the body may be altered by inhibitors and inducers of CYP3A4. (For a list of CYP3A4 inhibitors and ... It has also been identified in vitro as a strong inhibitor of CYP27A1 (cholesterol 27-hydroxylase) and as an inhibitor of ... usually at 50 mg/day Peripheral precocious puberty in boys at 12.5 to 100 mg/day in combination with an aromatase inhibitor ...

https://en.wikipedia.org/wiki/Bicalutamide

In addition to the BATT study, a variety of case reports and series of bicalutamide in combination with an aromatase inhibitor ... Bicalutamide is used to block the actions of androgens in the condition, while the aromatase inhibitor is used to decrease ... Bicalutamide is used in combination with an aromatase inhibitor such as anastrozole or letrozole in the treatment of peripheral ... ISBN 978-1-4419-1794-2. Diaz-Thomas, Alicia; Shulman, Dorothy (2010). "Use of aromatase inhibitors in children and adolescents ...

https://en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

de Ronde W, de Jong FH (June 2011). "Aromatase inhibitors in men: effects and therapeutic options". Reprod. Biol. Endocrinol. ( ... Estrogen insensitivity syndrome Aromatase excess syndrome Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT (2006). " ... Very rare causes include aromatase deficiency and estrogen insensitivity syndrome. Medications can also be a cause of ... Khosla S (September 2008). "Estrogen and bone: insights from estrogen-resistant, aromatase-deficient, and normal men". Bone. 43 ...

https://en.wikipedia.org/wiki/Hypoestrogenism

... and third-generation aromatase inhibitors. In addition to its activity as an aromatase inhibitor, testolactone also reportedly ... 935-. ISBN 978-1-351-78989-9. Testolactone at DrugBank.ca Dunkel L (July 2006). "Use of aromatase inhibitors to increase final ... Testolactone (INN, USAN) (brand name Teslac) is a non-selective, irreversible, steroidal aromatase inhibitor which is used as ... In vitro studies report that the aromatase inhibition may be noncompetitive and irreversible, and could possibly account for ...

https://en.wikipedia.org/wiki/Testolactone

... dipeptidyl peptidase-4 inhibitors, SGLT2 inhibitors, and glucagon-like peptide-1 analogs.[87] As of 2015 there was no ... aromatase excess syndrome. *Androgen receptor (Androgen insensitivity syndrome). *general: Hypogonadism (Delayed puberty) ... There is some evidence that angiotensin converting enzyme inhibitors (ACEIs) are superior to other inhibitors of the renin- ... 2015 American Diabetes Association recommendations are that people with diabetes and albuminuria should receive an inhibitor of ...

https://en.wikipedia.org/wiki/Type_2_diabetes_mellitus

Robert A. Copeland (2013). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and ... Suhara, K., Ohashi, K., Takahashi, K. and Katagiri, M. (1988). "Aromatase and nonaromatizing 10-demethylase activity of adrenal ... Kupfer, D., Miranda, G.K., Navarro, J., Piccolo, D.E. and Theoharides, A.D. (1979). "Effect of inducers and inhibitors of ... http://books.google.com/books/about/Evaluation_of_Enzyme_Inhibitors_in_Drug.html?id=l2rMy8QNUk0C. ...

https://sh.wikipedia.org/wiki/Nespecifična_monooksigenaza

is modified to include binding of the inhibitor to the free enzyme:. EI. +. S. ⇌. k. 3. k. −. 3. E. +. S. +. I. ⇌. k. −. 1. k. ... is the inhibitor concentration.. V. max. {\displaystyle V_{\max }}. remains the same because the presence of the inhibitor can ... To compute the concentration of competitive inhibitor [. I. ]. {\displaystyle {\ce {[I]}}}. that yields a fraction f. V. 0. {\ ... At this point, we can define the dissociation constant for the inhibitor as K. i. =. k. −. 3. /. k. 3. {\displaystyle K_{i}=k ...

https://en.wikipedia.org/wiki/Competitive_inhibition

Aromatase inhibitors (e.g., anastrozole). *GnRH agonists (e.g., GnRH). Antigonadotropins. *Sex steroid agonists (via negative ... GnRH receptor agonists; GnRH blockers; GnRH inhibitors; Antigonadotropins. Use. Fertility medicine; Prostate cancer; Breast ...

https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone_agonist

cytotoxic drugs, therapeutic antibodies, sex hormones, aromatase inhibitors, somatostatin inhibitors, recombinant interleukins ... Anti-allergy: mast cell inhibitors. *Anti-glaucoma: adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors/ ... HMG-CoA reductase inhibitors (statins) for lowering LDL cholesterol inhibitors: hypolipidaemic agents. ... monoamine oxidase inhibitors, lithium salts, and selective serotonin reuptake inhibitors (SSRIs)), antiemetics, Anticonvulsants ...

https://en.m.wikipedia.org/wiki/Pharmaceutical

aromatase inhibitor. *clomifene. *FSH. *GnRH agonists. *Gonadotropins *menotropins. *hCG. In vitro fertilisation (IVF). and ...

https://en.wikipedia.org/wiki/Intracytoplasmic_sperm_injection?wprov=sfla1

Structure of letrozole, an oral nonsteroidal aromatase inhibitor for the treatment of certain breast cancers. ... Structure of fadrozole, an aromatase inhibitor for the treatment of breast cancer. ... Structure of citalopram, an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class. ...

https://en.m.wikipedia.org/wiki/Nitrile

His lab has synthesized a number of aromatase inhibitors using equine aromatase as a model.[6][non-primary source needed] His ... Séralini G, Moslemi S (June 2001). "Aromatase inhibitors: past, present and future". Molecular and Cellular Endocrinology. 178 ... The general area of his lab's research focuses on the endocrine system,[5] in particular the enzyme aromatase. ... Lemazurier E, Sourdaine P, Nativelle C, Plainfossé B, Séralini G (June 2001). "Aromatase gene expression in the stallion". ...

https://en.m.wikipedia.org/wiki/Gilles-Éric_Séralini

Richards JA, Brueggemeier RW (June 2003). "Prostaglandin E2 regulates aromatase activity and expression in human adipose ... inhibitors). COX. (PTGS). *Salicylic acids: Aloxiprin. *Aspirin (acetylsalicylic acid). *Benorilate (benorylate). *Carbasalate ...

https://ml.wikipedia.org/wiki/പ്രോസ്റ്റാഗ്ലാൻഡിൻ_EP3_റിസപ്റ്റർ

Aromatase inhibitors can cause diffuse muscle and joint pain and stiffness, and may increase the likelihood of osteoporosis and ... angiogenesis inhibitors like bevacizumab, known to sometimes cause bone pain; and surgery, which may produce post-operative ... the proteasome inhibitors such as bortezomib, and the platinum-based drugs cisplatin, oxaliplatin and carboplatin. Whether CIPN ...

https://en.wikipedia.org/wiki/Causes_of_cancer_pain

... estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer". Cancer Research. ...

https://en.m.wikipedia.org/wiki/Diethylstilbestrol

aromatase inhibitor. *clomifene. *FSH. *GnRH agonists. *Gonadotropins *menotropins. *hCG. In vitro fertilisation (IVF). and ...

https://en.wikipedia.org/wiki/Pregnancy_reduction,_multifetal

... is the greatest peripheral source of aromatase in both males and females,[citation needed] contributing to the ... Plasminogen activator inhibitor-1 (PAI-1). *TNFα. *IL-6. *Leptin. *Estradiol (E2) ...

https://en.wikipedia.org/wiki/Adipose

Menopausal hormone therapy, clonidine, gabapentin, selective serotonin reuptake inhibitors[5][6]. Menopause, also known as the ... After menopause, estrogen continues to be produced mostly by aromatase in fat tissues and is produced in small amounts in many ... or selective serotonin reuptake inhibitors.[5][6] Exercise may help with sleeping problems.[5] While MHT was once routinely ... "Minireview: aromatase and the regulation of estrogen biosynthesis--some new perspectives". Endocrinology. 142 (11): 4589-94. ...

https://en.wikipedia.org/wiki/Menopausal_symptoms

Three classes of diabetes medications - GLP-1 agonists, DPP-4 inhibitors, and SGLT2 inhibitors- are also thought to slow the ... aromatase excess syndrome. *Androgen receptor (Androgen insensitivity syndrome). *general: Hypogonadism (Delayed puberty) ... ACE inhibitors[3]. Diabetic nephropathy(DN), also known as diabetic kidney disease,[4] is the chronic loss of kidney function ... Angiotensin-converting-enzyme inhibitors (ACEi), as well as angiotensin II receptor blockers (ARBs), are particularly helpful ...

https://en.wikipedia.org/wiki/Diabetic_nephropathy

Aromatase inhibitors are medications that prevent estrogen production in the adrenal glands and adipose tissue. They have fewer ...

https://en.wikipedia.org/wiki/BRCA_mutation

It can be used in combination with an aromatase inhibitor (such as letrozole) to treat HR-positive, HER2-negative advanced or ... Ribociclib, sold under the brand name Kisqali,[1] is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of ... When used in combination with other drugs such as an ALK or an MEK inhibitor, ribociclib has been shown to have a synergistic ... Examples of such inhibitors include ketoconazole and similar antifungal drugs, ritonavir, clarithromycin, as well as grapefruit ...

https://en.wikipedia.org/wiki/Ribociclib

Aromatase inhibitors. *Exercise physiology. *Drugs in sport. *World Anti-Doping Agency prohibited substances ... 4-OHT has moderate anabolic, mild androgenic, and anti-aromatase properties and is similar to the steroid clostebol (4- ...

https://en.wikipedia.org/wiki/4-Hydroxytestosterone

Reassurance, aromatase inhibitors, SERMs, or surgery. The development of gynecomastia is usually associated with benign ... Wit JM, Hero M, Nunez SB (October 2011). "Aromatase inhibitors in pediatrics". Nature Reviews. Endocrinology. 8 (3): 135-47. ... Medications such as aromatase inhibitors have been found to be effective in rare cases of gynecomastia from disorders such as ... "Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development". Pediatrics. 121 ( ...

https://en.m.wikipedia.org/wiki/Gynecomastia

Aromatase inhibitors (e.g., anastrozole). *GnRH agonists (e.g., GnRH). Antigonadotropins. *Sex steroids (via negative feedback ...

https://fa.wikipedia.org/wiki/منوتروپین?match=en

The aromatase inhibitor aminoglutethimide induces the metabolism of tamoxifen.[2] Conversely, the aromatase inhibitor letrozole ... Aromatase Inhibitors + Tamoxifen. Cite uses deprecated parameter ,deadurl=. (help). *^ Eugster EA, Shankar R, Feezle LK, ... an aromatase inhibitor).[48]. A significant number of tamoxifen-treated breast cancer patients experience a reduction of libido ... has been found to act as a potent competitive aromatase inhibitor (IC50 = 90 nM), and may also be involved in the ...

https://en.m.wikipedia.org/wiki/Tamoxifen

Hilário SG, Bozzini N, Borsari R, Baracat EC (January 2009). "Action of aromatase inhibitor for treatment of uterine leiomyoma ...

https://en.m.wikipedia.org/wiki/Dysmenorrhea

... of NSAID expenditures were for COX-2 inhibitors. Over the period of the study, COX-2 inhibitors rose from 10.03% of total ... "COX-2 Inhibitors and Cancer". Fact Sheet. United States National Cancer Institute. Archived from the original on May 9, 2008.. ... COX-2 inhibitors appear to work as well as nonselective NSAIDS.[5] They have not been compared to other treatment options such ... COX-2 inhibitors and cardiovascular risk". Science. 336 (6087): 1386-7. Bibcode:2012Sci...336.1386C. doi:10.1126/science. ...

https://en.wikipedia.org/wiki/COX_inhibitor

aromatase inhibitor. *clomifene. *FSH. *GnRH agonists. *Gonadotropins *menotropins. *hCG. In vitro fertilisation (IVF). and ...

https://en.wikipedia.org/wiki/Sex_selection

steroid biosynthesis: aromatase synthesizes estrogen. 1 subfamily, 1 gene. CYP19A1 CYP20. unknown function. 1 subfamily, 1 gene ... Inhibitors and certain substrates that bind directly to the heme iron give rise to the type II difference spectrum, with a ... CYP19A (P450arom, aromatase) in endoplasmic reticulum of gonads, brain, adipose tissue, and elsewhere catalyzes aromatization ... Some CYPs metabolize only one (or a very few) substrates, such as CYP19 (aromatase), while others may metabolize multiple ...

https://en.wikipedia.org/wiki/CYP450

Hilário SG, Bozzini N, Borsari R, Baracat EC (2008). "Action of aromatase inhibitor for treatment of uterine leiomyoma in ... Chantler I, Mitchell D, Fuller A (2008). "The effect of three cyclo-oxygenase inhibitors on intensity of primary dysmenorrheic ...

https://te.wikipedia.org/wiki/డిస్మెనోరియా

... aromatase inhibitors - are more effective than tamoxifen for reducing mortality among women with ER-positive breast cancer. ... Aromatase inhibitors lower estrogen levels by preventing the enzyme aromatase - found in fat tissue - from changing other ... Aromatase inhibitors reduced breast cancer mortality by 40%. For their study, the team analyzed the data of nine clinical ... Aromatase inhibitors remove only the tiny amount of estrogen that remains in the circulation of women after the menopause - but ...

https://www.medicalnewstoday.com/articles/297297.php

Type I inhibitors that are steroidal aromatase inhibitors and type II inhibitors that are non-steroidal aromatase inhibitors. ... Aromatase inhibitors Steroidal aromatase inhibitors Chumsri, Saranya (2015-05-06). "Clinical utilities of aromatase inhibitors ... steroidal aromatase inhibitors (SAIs, type 1 inhibitors) and non-steroidal aromatase inhibitors (type 2 inhibitors) that is ... Non-Steroidal Aromatase Inhibitors (NSAIs) are one of two categories of aromatase inhibitors (AIs). AIs are divided into two ...

https://en.wikipedia.org/wiki/Non_steroidal_aromatase_inhibitors

This F1000 commentary rates a meta-analysis on aromatase inhibitors and when their use should be discouraged as Changes ... When Are Aromatase Inhibitors Wrong for Breast Cancer Patients? Classified by F1000 as Changes Clinical Practice. ... Changes clinical practice: The risks and benefits of adjuvant aromatase inhibitors (AIs) should be weighed carefully, ... This meta-analysis confirms that an aromatase inhibitor (AI) is not the best therapy for all postmenopausal women with hormone- ...

https://www.medscape.com/viewarticle/756567

Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a ... There are two types of aromatase inhibitors approved to treat breast cancer: Irreversible steroidal inhibitors, such as ... Chen S, Kao YC, Laughton CA (1997). "Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase". J ... some natural elements have aromatase inhibiting effects, such as damiana leaves. The development of aromatase inhibitors was ...

https://en.wikipedia.org/wiki/Aromatase_inhibitor

Aromatase inhibitors and tamoxifen are two types of hormonal therapy.. A study found that women diagnosed with early-stage, ... The aromatase inhibitors can weaken bones and make women more likely to break a bone, though this is uncommon. Tamoxifen ... In other cases, women take tamoxifen for 2 or 3 years and then switch to an aromatase inhibitor until the hormonal therapy has ... Women who got tamoxifen for 2 to 3 years followed by an aromatase inhibitor had the same risk of cardiovascular problems as ...

https://www.breastcancer.org/research-news/20101210

More: What Are Aromatase Inhibitors?. In 2005, Breast Cancer Action launched an online survey to collect information from women ... Aromatase inhibitors (AIs) have quickly become standard treatments for postmenopausal women with estrogen-receptor-positive ... These reports are dedicated to the women who generously took the time to respond to BCAs Aromatase Inhibitor Side Effects ... In June 2008, BCA released the follow-up report, Side Effects Revisited: Womens Experiences with Aromatase Inhibitors based on ...

https://bcaction.org/our-take-on-breast-cancer/treatment/aromatase-inhibitors/

Tag: aromatase inhibitor. AcupunctureCancerClinical Trials. Acupuncture versus breast cancer treatment-induced joint pain: ... The investigators behind a recent clinical trial testing acupuncture to treat joint pain caused by aromatase inhibitors used to ...

https://sciencebasedmedicine.org/tag/aromatase-inhibitor/

Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast ... The first section covers general knowledge about aromatase inhibitors, including regulation of aromatase genes, and structure ... Resistance to Aromatase Inhibitors in Breast Cancer. Editors. * Alexey Larionov Series Title. Resistance to Targeted Anti- ... Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast ...

https://www.springer.com/us/book/9783319179711?utm_campaign=bookpage_about_buyonpublisherssite&utm_medium=referral&utm_source=springerlink

Tags: 50 to 64, 65 and older, Estrogen-Receptor Positive, Aromatase Inhibitors, Arimidex (chemical name: anastrozole), Aromasin ... Aromatase inhibitors arent commonly used to reduce recurrence risk in premenopausal women. Still, in some cases a ... "The treatment with aromatase inhibitors worked significantly better in the non-smoking patients," she continued. "However, we ... "Smokers who were treated with aromatase inhibitors had a three times higher risk of recurrence of breast cancer compared with ...

https://www.breastcancer.org/research-news/smoking-may-make-ais-less-effective

Another aromatase inhibitor, androst-4-ene-3,6,17-trione, has been efficiently prepared using PCC on montmorillonite K10, under ... Improved syntheses of aromatase inhibitors and neuroactive steroids efficient oxidations and reductions at key positions for ... Using testosterone as starting material, a new short synthesis of an aromatase inhibitor, 4-OHA, has been achieved through ...

https://www.mendeley.com/papers/improved-syntheses-aromatase-inhibitors-neuroactive-steroids-efficient-oxidations-reductions-key-pos/

Taking the aromatase inhibitor exemestane (Aromasin) for primary prevention of breast cancer may weaken the bones, researchers ... Aromatase Inhibitor Linked to Bone Loss. Taking the aromatase inhibitor exemestane (Aromasin) for primary prevention of breast ... Taking the aromatase inhibitor exemestane (Aromasin) for primary prevention of breast cancer may weaken the bones, researchers ... Loss of bone density and fractures are known risks of aromatase inhibitors in breast cancer survivors taking the drugs to ...

https://www.medpagetoday.com/hematologyoncology/breastcancer/31042

SEARCH RESULTS for: Aromatase Inhibitors [Drug Class] (65 results) * Share : JavaScript needed for Sharing tools. Bookmark & ...

https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Aromatase%20Inhibitors&searchdb=class

Aromatase inhibitors after Tamoxifen Ten Year Survival With Aromatase Inhibitor Use Evista as adjuvant therapy DCIS Hormone ... it is reasonable to believe that aromatase inhibitors should be effective.. Aromatase inhibitors prevent estrogen synthesis, ... Can aromatase inhibitors be used to prevent reccurrence of malignant mammary tumors in dogs? If so, which one is indicated, and ... Aromatase Inhibitors or Tamoxifen Canine Mammary Tumors & Spaying Drug/Herbal Interactions with Arimidex Tamoxifen Therapy for ...

https://www.oncolink.org/frequently-asked-questions/cancers/vet/veterinary-oncology/aromatase-inhibitors-in-mammary-tumors

c) a history of generalized musculoskeletal pain that began or worsened since starting treatment with the aromatase inhibitor. ... 3.Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.Breast Cancer Res Treat. ... Fifty percent of women taking aromatase inhibitors reported musculoskeletal pain, and up to 30% reported fatigue. The results ... multiple studies confirm a reduction in side effects of aromatase inhibitors The most recent of the four studies was presented ...

http://archive.constantcontact.com/fs026/1102452079631/archive/1110542592042.html

... adjuvant treatment with aromatase inhibitors does not raise the risk for cardiovascular events, a researcher said. ... The aromatase inhibitors are rapidly replacing tamoxifen as the adjuvant treatment of choice for early breast cancer in ... Dickler said, "When youre comparing an [aromatase inhibitor] to tamoxifen, its easy to forget that tamoxifen does have lipid- ... Monnier concluded that comparisons of aromatase inhibitors with placebo may be more useful in determining the risks associated ...

https://www.medpagetoday.com/hematologyoncology/breastcancer/9180

The enzyme that is responsible for this conversion is aromatase, made primarily in fat and other tissue, especially in the ... Also, there will be information from trials testing aromatase inhibitors following 5 years of tamoxifen. The other aromatase ... There are ongoing trials that will anwer the questions of 2-3 years of tamoxifen followed by an aromatase inhibitor. For newly ... The first such study to be reported was a comparison of the aromatase inhibitor anastrozole (trade name Arimidex) to tamoxifen ...

http://www.cancersupportivecare.com/aromatase.html

This topic contains 21 study abstracts on Aromatase Inhibitor Drugs indicating they may contribute to Breast Cancer, Drug- ... Problem Substances : Aromatase Inhibitor Drugs, Letrozole (trade name Femera). Adverse Pharmacological Actions : Endocrine ... 24 Abstracts with Aromatase Inhibitor Drugs Research. Filter by Study Type. Animal Study. ... The aromatase inhibitor letrozole has endocrine disruptive properties on hypothalamic-pituitary output in normal women.Feb 24, ...

https://www.greenmedinfo.com/toxic-ingredient/aromatase-inhibitor-drugs

Aromatase inhibitors, when used for up to three years in combination with growth hormone, may effectively and safely help very ... Aromatase Inhibitor, Growth Hormone, Adolescent, Boys, Puberty, Clinical Trial, Endocrinology, Endocrine Society, ENDO 2016 ... Newswise - Boston, MA- Aromatase inhibitors, when used for up to three years in combination with growth hormone, may ... "This work provides the longest treatment and follow up reported using aromatase inhibitors (AIs) in adolescent males, showing ...

https://www.newswise.com/articles/aromatase-inhibitors-plus-growth-hormone-may-help-short-adolescent-boys-grow-taller

... by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women ... aromatase inhibitor listen (uh-ROH-muh-tays in-HIH-bih-ter) A drug that prevents the formation of estradiol, a female hormone, ... by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women ...

https://www.cancer.gov/publications/dictionaries/cancer-terms/def/aromatase-inhibitor?redirect=true

Arimedex aromatase inhibitor and gynomastia, male breast tissue development prevention used by some body builders and hair loss ... It is also an inhibitor of aromatase, and it is a better aromatase inhibitor than a desmolase inhibitor. About 250 mg/day is ... With nandrolone, an aromatase inhibitor will be of no use, because aromatase is not used in the aromatization of nandrolone. A ... Arimidex Aromatase Inhibitor as a treatment for Gynomastia. It is a known fact that certain hair loss treatments can cause ...

https://hairsite.com/baldness-encyclopedia/baldness-encyclopediaarimidex-aromatase-inhibitor-and-gynomastia/

... an aromatase inhibitor currently used to prevent breast cancer recurrence in postmenopausal women, shows promise in the ... "This study demonstrates the potential of aromatase inhibitors to significantly and rapidly reduce disease severity and pain, ... an aromatase inhibitor currently used to prevent breast cancer recurrence in postmenopausal women, shows promise in the ... We need to attack the root problem - the aromatase - in order to eliminate this cycle, halt the local production of estrogen ...

http://www.prohealth.com/library/showarticle.cfm?libid=10264

... serms selective estrogen receptor modulators. ai aromatase inhibitor. ... Are aromatase inhibitors and estrogen blockers the same? Confused on the subject a lot of info to remember not just ai s but ... Re: Are aromatase inhibitors and estrogen blockers the same? bro what you need them for? if for gyno use letro ... Re: Are aromatase inhibitors and estrogen blockers the same? SERMs block estrogen from feedbacking into the pit glands. AIs ...

https://www.elitefitness.com/forum/anabolic-steroids/aromatase-inhibitors-estrogen-blockers-same-1504234.html?s=39a16b3a86373c230d06ac9e98efad0e

... @media screen and (max-width: 468px) { .video-detail .doc- ... are typically prescribed aromatase inhibitors (AIs), a class of drugs that includes anastrozole, letrozole and exemestane, for ... AIs stop the production of estrogen by blocking the enzyme aromatase, which converts the hormone androgen into estrogen. But ...

https://www.curetoday.com/view/exercise-improves-joint-pain-associated-with-aromatase-inhibitors

... buy latest estrogen aromatase inhibitor direct from 103 Chongqing estrogen aromatase inhibitor Factories. ... aromatase inhibitors , aromatase inhibitors side effects , aromatase inhibitor , aromatase inhibitor powder , aromatase ... aromatase inhibitors bodybuilding , anastrozole aromatase inhibitor , aromatase inhibitors for men , aromatase inhibitor ... anti-estrogen aromatase inhibitor , anti estrogen aromatase inhibitor , estrogen aromatase , estrogen receptor inhibitor , ...

http://www.himfr.com/buy-estrogen-aromatase-inhibitor/provinces-31000000.html

A. D. T. Diaz-Thomas et al., "Too much of a good thing: polycythemia and aromatase inhibitors," AAP Capital Letters, abstract ... J.-M. A. Nabholtz, "Long-term safety of aromatase inhibitors in the treatment of breast cancer," Therapeutics and Clinical Risk ... Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer. Sri Lakshmi Hyndavi ... A. Iyengar and D. Sheppard, "A case of erythrocytosis in a patient treated with an aromatase inhibitor for breast cancer," Case ...

https://www.hindawi.com/journals/crihem/2015/784783/ref/

Recent advances in breast cancer treatment include the advent of aromatase inhibitors (AIs) in the adjuvant setting with better ... Venturini M, Del Mastro L (2006) Safety of adjuvant aromatase inhibitor therapy. Cancer Treat Rev 32(7):548-556PubMedCrossRef ... Pritchard KI, Abramson BL (2006) Cardiovascular health and aromatase inhibitors. Drugs 66(13):1727-1740PubMedCrossRefGoogle ... Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. NEJM 348(24):2432-2442CrossRefGoogle Scholar ...

https://link.springer.com/article/10.1007%2Fs10549-006-9470-y

Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer. Sri Lakshmi Hyndavi ... Aromatase inhibitors (AIs) are most commonly used for breast cancer patients with hormone receptor positive disease. Although ... We discuss the pathophysiology of aromatase inhibitor-induced erythrocytosis and reference of similar cases reported in the ... the side effect profile of aromatase inhibitors is well known, including common side effects like arthralgia, bone pain, ...

https://www.hindawi.com/journals/crihem/2015/784783/abs/

Aromatase inhibitors (AIs) are used to try to stop breast cancer from forming or returning after treatment in women who are in ... Preventing Sexual Dysfunction in Women on Aromatase Inhibitors. Trial Phase:. Phase 2. Minimum Age:. 18 Years. Maximum Age:. N/ ... Preventing Sexual Dysfunction in Women on Aromatase Inhibitors. If you agree to take part in this study, you will be randomly ... 3. Began adjuvant therapy with an aromatase inhibitor 12 to 18 months before survey sent. out (Benchmark Survey only). 4. Was ...

http://www.knowcancer.com/cancer-trials/NCT01603303/

Home > RHL Topics > Gynaecology, infertility and cancers > Gynaecological cancers and disorders > Aromatase inhibitor for ... Findings of the review: Aromatase inhibitors are a new class of drugs that has been used to treat breast and ovarian cancer. ... Both in vitro studies and clinical trials have suggested that use of the aromatase inhibitors (AIs), a class of anti-oestrogens ... Citation: Song H, Lu D, Navaratnam K, Shi G. Aromatase inhibitors for uterine fibroids.Cochrane Database of Systematic Reviews ...

https://extranet.who.int/rhl/topics/gynaecology-infertility-and-cancers/gynaecology-and-infertility/aromatase-inhibitor-uterine-fibroids

... aromatase).. Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced ... However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess ...

https://rd.springer.com/book/10.1007/978-3-7643-8693-1

The aromatase inhibitors include anastrozole (Armidex), letrozole (Femara) and exemastane (Aromasin). (news-medical.net)
The aromatase inhibitors anastrozole and letrozole are similar in their pharmacokinetic properties and both have a dosing schedule of once daily due to a half life (time taken for a the amount of a drug present in the body to become halved) of approximately 48 hours for each of them. (news-medical.net)
Ovarian stimulation with the aromatase inhibitor letrozole has been proposed for ovulation induction in order to treat unexplained female infertility. (wikipedia.org)
The other aromatase inhibitors, letrozole (Femara) and exemestane (Aromasin) are also being tested in early stage breast cancer. (cancersupportivecare.com)
Northwestern Memorial Hospital physician publishes findings of pioneering study in February issue of Fertility and Sterility Letrozole (Femara), an aromatase inhibitor currently used to prevent breast cancer recurrence in postmenopausal women, shows promise in the treatment of endometriosis, according to the results of a pioneering pilot study conducted by Serdar Bulun, M.D., chief of the Division of Reproductive Biology Research at Northwestern Memorial Hospital. (prohealth.com)
The third-generation aromatase inhibitors (AIs)-anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin)-are increasingly being found to improve upon the efficacy we observed for decades with tamoxifen. (cancernetwork.com)
Postmenopausal women whose breast cancer is fueled by hormones (estrogen receptor-positive breast cancer) are typically prescribed aromatase inhibitors (AIs), a class of drugs that includes anastrozole, letrozole and exemestane, for five years after surgery or primary treatment. (curetoday.com)
Among a new line of infertility treatment drugs aimed at balancing hormone levels such as estrogen and testosterone are aromatase inhibitors in the form of anastrozole (Arimidex) and letrozole (Femara). (sharedjourney.com)
Aromatase inhibitors used in treating fertility problems are known as letrozole (Femara) and anastrozole (Arimidex). (wdxcyber.com)
[email protected] Skype:live:kathelin_4 WhataApp:+8618872220706 Letrozole description: Femara is a powerful Aromatase Inhibitor that was developed to fight breast cancer. (himfr.com)
Femara (letrozole) is an extensively investigated, marketed aromatase inhibitor (AI) widely used as treatment in the maintenance phase of estrogen-receptor (ER) positive breast cancer, as it inhibit the synthesis of estrogens. (clinicaltrials.gov)
Tamoxifen works by blocking oestrogen's effects on cells, whereas letrozole, which belongs to a class of drugs called aromatase inhibitors , works by preventing the body from making oestrogen in the first place. (cancerresearchuk.org)
If you have hormone receptor-positive breast cancer, hormone therapy with tamoxifen and/or an aromatase inhibitor (anastrozole, letrozole or exemestane) is a key part of your treatment. (komen.org)
Oestrogen actions are mediated through oestrogen receptor (ER), and endocrine therapies, such as aromatase inhibitors (i.e., letrozole, anastrozole and exemestane) and tamoxifen, are used in patients with ER-positive invasive carcinoma to block the oestrogen actions. (nature.com)
Here, we studied the mechanisms and signaling pathways of cell growth, cell cycle progression, and apoptosis induced by three aromatase inhibitors: letrozole (Let), anastrozole, and 4-hydroxyandrostenedione in comparison with estrogen withdrawal (E2W) and antiestrogens Tam and faslodex. (aacrjournals.org)
Originally used in the treatment of breast cancer and prostate cancer, aromatase inhibitors may also provide solutions to common fertility problems in the form of letrozole (Femara) and anastrozole (Arimidex). (gettingpregnant.co.uk)
Following promising data for metastatic breast cancer in terms of efficacy and safety profile, third-generation aromatase inhibitors (AI), anastrozole, letrozole, and exemestane, underwent a full development in early setting. (dovepress.com)
HealthDay News) - Body mass index (BMI) affects the level of estradiol and estrone sulfate suppression achieved when treating postmenopausal women with estrogen receptor (ER)-positive breast cancer with either of two aromatase inhibitors, anastrozole or letrozole . (empr.com)
At higher BMI, the levels of estrogen were greater for patients receiving treatment with both aromatase inhibitors, and this effect was significant with letrozole. (empr.com)
Letrozole is an Aromatase inhibitor. (adooq.com)
When the study ended, 95% of women who had 10 years of aromatase inhibitor therapy (Letrozole) had disease-free survival (meaning they did not develop a recurrence or a new cancer in the other breast), while 91% of women who had 5 years of aromatase inhibitor therapy had disease-free survival at the study endpoint. (facingourrisk.org)
Advanced breast cancer: diagnosis and treatment ' (NICE clinical guideline 81) recommends that if the disease is not imminently life threatening, or does not need early relief of symptoms because of significant visceral organ involvement, women who are postmenopausal and have hormone-receptor-positive breast cancer should be offered an aromatase inhibitor such as anastrozole or letrozole. (nice.org.uk)
Effects of 17[alpha]-methyltestosterone and aromatase inhibitor letrozole on sex reversal, gonadal structure, and growth in yellow catfish pelteobagrus fulvidraco. (thefreelibrary.com)
In the POETIC trial , 4,480 postmenopausal patients (median age, 67) with early-stage estrogen receptor-positive breast cancer were analyzed after randomization 2:1 to either a perioperative aromatase inhibitor (letrozole at 2.5 mg/d or anastrozole at 1 mg/d), for 14 days prior to and 14 days following surgery, or no perioperative aromatase inhibitor. (ascopost.com)
Type I inhibitors such as exemestane are considered steroidal compounds, and AI's such as anastrozole and letrozole are in the Type II group, which are non-steroidal drugs. (ironmagazine.com)

The advantages of using aromatase inhibitors over other hormonal agents such as tamoxifen include a decrease in vaginal discharge, a reduced risk of blood clotting and less risk of womb cancer. (news-medical.net)
Aromatase inhibitors - which work by lowering estrogen levels - were found to be more effective than tamoxifen in reducing deaths among women with ER-positive breast cancer. (medicalnewstoday.com)
In the US, aromatase inhibitors are currently used to treat early-stage breast cancer in postmenopausal women who have been treated with tamoxifen for around 2-3 years. (medicalnewstoday.com)
Previous research suggests aromatase inhibitors are more effective for reducing breast cancer recurrence than tamoxifen, though how they impact survival has been unclear. (medicalnewstoday.com)
The women in the trials had either received no hormonal therapy or had used aromatase inhibitors or tamoxifen for at least 5 years. (medicalnewstoday.com)
Our global collaboration has revealed that the risk of postmenopausal women with the most common form of breast cancer dying of their disease is reduced by 40% by taking 5 years of an aromatase inhibitor - a significantly greater protection than that offered by tamoxifen. (medicalnewstoday.com)
Aromatase inhibitors and tamoxifen are two types of hormonal therapy. (breastcancer.org)
A study found that women diagnosed with early-stage, hormone-receptor-positive breast cancers who were treated with an aromatase inhibitor were 26% more likely to have cardiac problems -- heart attack, heart-related chest pain (angina), or heart failure -- compared to women treated with tamoxifen. (breastcancer.org)
Many postmenopausal women take hormonal therapy -- either an aromatase inhibitor or tamoxifen -- after surgery and other treatments for hormone-receptor-positive, early-stage breast cancer. (breastcancer.org)
In many cases, one hormonal therapy medicine -- tamoxifen or an aromatase inhibitor -- is taken for 5 years. (breastcancer.org)
In other cases, women take tamoxifen for 2 or 3 years and then switch to an aromatase inhibitor until the hormonal therapy has been taken for a total of 5 years. (breastcancer.org)
So you might take tamoxifen for 2 years and an aromatase inhibitor for 3 years. (breastcancer.org)
Five years of an aromatase inhibitor is somewhat better than 5 years of tamoxifen for reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer -- about 20% better overall. (breastcancer.org)
Sequential therapy (tamoxifen for 2 to 3 years followed by an aromatase inhibitor) can reduce the risk of recurrence about the same as 5 years of an aromatase inhibitor. (breastcancer.org)
3.4% of the women treated with 5 years of tamoxifen had a cardiovascular problem compared to 4.2% of the women treated with 5 years of an aromatase inhibitor. (breastcancer.org)
Women who got tamoxifen for 2 to 3 years followed by an aromatase inhibitor had the same risk of cardiovascular problems as women who got 5 years of tamoxifen. (breastcancer.org)
In rare cases, both tamoxifen and the aromatase inhibitors can lead to dangerous blood clots. (breastcancer.org)
This risk is higher with tamoxifen and lower with an aromatase inhibitor. (breastcancer.org)
Both tamoxifen and the aromatase inhibitors have been linked to a small risk of uterine cancer. (breastcancer.org)
This study found that broken bones due to hormonal therapy were 47% more likely in women who got 5 years of an aromatase inhibitor compared to women who got 5 years of tamoxifen. (breastcancer.org)
Research also has shown that hot flashes and night sweats -- called vasomotor symptoms -- are side effects of both tamoxifen and the aromatase inhibitors, though they're more common with tamoxifen. (breastcancer.org)
We are not aware of any studies published on the effect of aromatase inhibitors in dogs with mammary carcinoma, but based on the fact that many of these tumors are estrogen-dependent, express estrogen receptors, and respond to tamoxifen, it is reasonable to believe that aromatase inhibitors should be effective. (oncolink.org)
Aromatase inhibitors prevent estrogen synthesis, whereas tamoxifen works by blocking the estrogen receptor. (oncolink.org)
Any differences in the prevalence of hypercholesterolemia or cardiovascular events between the aromatase inhibitors and tamoxifen could be explained by the well-known cardioprotective and lipid-lowering effects of tamoxifen, he said, and not an increased risk from the drugs themselves. (medpagetoday.com)
There are no differences between [aromatase inhibitors and tamoxifen] in terms of safety issues or cardiovascular issues. (medpagetoday.com)
The aromatase inhibitors are rapidly replacing tamoxifen as the adjuvant treatment of choice for early breast cancer in postmenopausal women, a population with comorbidities like diabetes and hypertension. (medpagetoday.com)
But trials that compare aromatase inhibitors with tamoxifen have raised some concerns about whether these medications increase cardiovascular risk. (medpagetoday.com)
Dr. Monnier analyzed several trials involving the aromatase inhibitors in comparison with tamoxifen or placebo. (medpagetoday.com)
Dr. Dickler said, "When you're comparing an [aromatase inhibitor] to tamoxifen, it's easy to forget that tamoxifen does have lipid-lowering effects. (medpagetoday.com)
Dr. Monnier concluded that comparisons of aromatase inhibitors with placebo may be more useful in determining the risks associated with treatment, considering the protective effect of tamoxifen. (medpagetoday.com)
The first such study to be reported was a comparison of the aromatase inhibitor anastrozole (trade name Arimidex) to tamoxifen or to a combination of the two drugs. (cancersupportivecare.com)
There are ongoing trials that will anwer the questions of 2-3 years of tamoxifen followed by an aromatase inhibitor. (cancersupportivecare.com)
Also, there will be information from trials testing aromatase inhibitors following 5 years of tamoxifen. (cancersupportivecare.com)
Recent advances in breast cancer treatment include the advent of aromatase inhibitors (AIs) in the adjuvant setting with better efficacy and toxicity profiles than tamoxifen. (springer.com)
The results from these studies also provide a rationale for directly comparing aromatase inhibitors with tamoxifen as first-line treatment in advanced disease. (cancernetwork.com)
Nevertheless, these two aromatase inhibitors have now successfully challenged tamoxifen as the gold standard of hormonal therapy in advanced breast cancer. (cancernetwork.com)
No data are yet available from various trials testing aromatase inhibitors as adjuvant therapy in breast cancer, although the large ATAC (Arimidex, Tamoxifen Alone and Combination) trial has now completed accrual of more than 9,000 patients. (cancernetwork.com)
Tamoxifen has traditionally been preferred over the use of aromatase inhibitors (AIs) in this group. (uspharmacist.com)
Professor Jack Cuzick, a Cancer Research UK epidemiologist based at Queen Mary, University of London, said: "This study confirms what we've known for some time - that the aromatase inhibitors are more effective than tamoxifen at delaying the return of breast cancer in postmenopausal women with hormone receptor-positive early breast cancer. (cancerresearchuk.org)
Or, your provider may switch you to another aromatase inhibitor (you may have less pain with a different drug) or recommend tamoxifen [ 90 ]. (komen.org)
Aromatase inhibitors cause a loss of bone density, which leads to higher rates of osteoporosis and bone fractures compared to tamoxifen [ 86 ]. (komen.org)
Although both aromatase inhibitors and tamoxifen can cause menopausal symptoms such as hot flashes, many of their side effects differ (see Figure 5.11 below). (komen.org)
Risk of the most serious cardiovascular events, cardiac ischemia and stroke, were not increased in breast cancer patients taking aromatase inhibitors compared with tamoxifen users. (oncologynurseadvisor.com)
Few women with invasive breast cancer who are treated with lumpectomy, radiation and five years of tamoxifen would benefit from taking an aromatase inhibitor after tamoxifen. (innovations-report.de)
A randomized study in a similar patient population has demonstrated a small disease free-survival benefit when these patients receive an aromotase inhibitor, such as femara, after completing 5 years of tamoxifen," said Gary Freedman, M.D., a radiation oncologist at Fox Chase Cancer Center and lead author of the study. (innovations-report.de)
For this study, we looked at women who were free of cancer after completing all therapy, including five years of tamoxifen, to better define which women would benefit from taking an aromatase inhibitor rather than recommending it for all women. (innovations-report.de)
After looking at all the factors of the women in this retrospective study, we believe the addition of an aromatase inhibitor to the five years of tamoxifen for all patients would result in only a 1 to 2 percent clinical benefit," explained Freedman. (innovations-report.de)
Women with-node positive breast cancer and women aged 60 years or younger would be the ones more likely to benefit from the addition of an aromatase inhibitor after completing the 5 years of tamoxifen. (innovations-report.de)
Aromatase inhibitors have recently been reported to be more effective than the antiestrogen tamoxifen (Tam) in treating breast cancer. (aacrjournals.org)
In this phase II trial, 67 postmenopausal women with advanced breast cancer whose disease had progressed after previous treatment with both tamoxifen and then an aromatase inhibitor were assessed. (presseportal.ch)
However, as aromatase inhibitors such as 'Arimidex' (anastrozole) have now demonstrated their superiority over tamoxifen in both the adjuvant setting and as first line therapy for advanced breast cancer, the changing treatment paradigm means that the efficacy and tolerability of 'Faslodex' following aromatase inhibitor therapy has become an important question for clinicians and patients alike. (presseportal.ch)
Well, tamoxifen causes far less bone loss than the aromatase inhibitors, so it is worth looking into if you might be able to use tamoxifen rather than one of the aromatase inhibitors. (algaecal.com)
Does anyone know, PLEASE, if there are treatments (Natural) that would work as well as Aromatase Inhibitors and Tamoxifen? (cancercompass.com)
The aromatase inhibitors (AIs) are becoming the preferred treatment over tamoxifen as adjuvant therapy for postmenopausal women with hormone-sensitive early breast cancer. (diva-portal.org)
Can I change from aromatase inhibitors to tamoxifen if I have side effects? (sharecare.com)
Aromatase inhibitors are a little bit better in treating breast cancer than tamoxifen, so the standard of care is to start with them. (sharecare.com)
The side effects are different, but some women tolerate tamoxifen better than aromatase inhibitors. (sharecare.com)
Tamoxifen an appropriate option for a woman who has tried the aromatase inhibitors and has experienced too many side effects such as joint pain and stiffness and worsening of osteoporosis. (sharecare.com)
Resistance to tamoxifen is linked to overexpression of HER2, and aromatase inhibitors show particular benefit in progesterone receptor (PR)-negative patients. (aacrjournals.org)
These results parallel data from the ATAC and Intergroup Exemastane Study trials which suggest that whereas PR-negative patients derive greater benefit from initial aromatase inhibitor treatment, PR status has no effect on response when given as delayed treatment to those disease free on tamoxifen after 3 years. (aacrjournals.org)
Identifying biological mechanisms behind tamoxifen resistance is important particularly as increasing clinical trials evidence implies superiority of aromatase inhibitors over tamoxifen ( 3 ). (aacrjournals.org)
It is not currently clear whether this superiority is the case for all ER-positive patients, or whether, as is widely predicted, there is a particular group of patients resistant to tamoxifen whose tumors may be sensitive to aromatase inhibitors. (aacrjournals.org)
There is however growing evidence that specific tumor markers may be used to identify tumors that exhibit resistance to tamoxifen as well as being linked to enhanced responsiveness to aromatase inhibitors ( 3 , 6 , 7 ). (aacrjournals.org)
The use of adjuvant endocrine therapy in women with hormone-sensitive breast cancer is divided, usually by menopausal status, between the selective estrogen receptor modulator tamoxifen and the newer class of drugs known as aromatase inhibitors. (menopause.org.au)
The aim of this study is to examine VTE risk following long-term use of aromatase inhibitor (AI) compared with tamoxifen use among breast cancer survivors. (springer.com)
The aromatase inhibitors, such as progestatifs, were developed to challenge tamoxifen efficacy, along with improved tolerability. (jle.com)
The third generation of aromatase inhibitors seems to provide significant gains in efficacy over tamoxifen for postmenopausal patients with hormone receptor positive breast cancer and they have already been approved in patients with metastatic disease. (jle.com)
Background - Aromatase inhibitors (AIs) may increase cardiovascular risk relative to tamoxifen in post-menopausal women with breast cancer. (ices.on.ca)
Conclusion - Aromatase inhibitors are associated with a higher risk of MI compared with tamoxifen. (ices.on.ca)
The cost of most drugs, aromatase inhibitors more specifically, were much too expensive for most people to afford, so drugs such as clomiphene, tamoxifen, and aminoglutethimide were used to control estrogen levels when using anabolic steroids. (ironmagazine.com)
Resistance to endocrine treatment, including both tamoxifen and aromatase inhibitors (AI), is marked by a shift from steroid dependence to growth factor dependence ( 1 ). (aacrjournals.org)

In addition to glucocorticoid replacement, the patient was commenced on growth hormone and a third-generation aromatase inhibitor, anastrozole, in an attempt to optimize his growth. (aappublications.org)
We report a novel approach to improve linear growth by using recombinant human growth hormone (GH) and anastrozole, an aromatase inhibitor (AI), in combination with glucocorticoids in a patient with late-presenting CYP11B1 deficiency with a markedly advanced bone age. (aappublications.org)
A double-blind placebo-controlled randomized phase II trial was performed to determine whether High Dose Vitamin D2 supplementation (HDD) in women receiving adjuvant anastrozole improves aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) and bone loss. (nih.gov)
Anastrozole is a third-generation nonsteroidal selective aromatase inhibitor. (adooq.com)
This phase I trial studies the side effects and the best dose of MK 2206 (Akt inhibitor MK2206) when given with anastrozole, fulvestrant, or anastrozole and fulvestrant in treating postmen. (bioportfolio.com)
We evaluated total IGF-1, IGF-2, IGF binding protein (IGFBP)-1 and IGFBP-3 in the blood of 34 postmenopausal advanced breast cancer patients (median age 63 years, range 41-85) treated with anastrozole, a non-steroidal structure aromatase inhibitor (NSS-AI). (professionalmuscle.com)
Anastrozole is in a class of drugs known as aromatase inhibitors (AI's. (ironmagazine.com)

Taking the aromatase inhibitor exemestane (Aromasin) for primary prevention of breast cancer may weaken the bones, researchers found. (medpagetoday.com)
There are two types of aromatase inhibitors approved to treat breast cancer: Irreversible steroidal inhibitors, such as exemestane (Aromasin), forms a permanent and deactivating bond with the aromatase enzyme. (wikipedia.org)
Effective Aromatase Inhibitor Exemestane / Aromasin Powder Description: Exemestane is a steroidal Aromatase Inhibitor (AI) that is most commonly known as Aromasin. (himfr.com)
The authors describe exemestane (Aromasin) as a steroidal, irreversible inactivator of aromatase. (cancernetwork.com)
In order to confirm findings from studies such as these, AstraZeneca are undertaking two large-scale international, randomised controlled trials of 'Faslodex' following aromatase inhibitor therapy, known as the EFECT trial (Evaluation of Fulvestrant versus Exemestane Clinical Trial) and the SOFEA trial (Study of 'Faslodex', Exemestane and 'Arimidex'), both of which are expected to confirm the efficacy and tolerability of 'Faslodex' in this important setting. (presseportal.ch)
Exemestane is an oral steroidal aromatase inhibitor that is used in ER-positive breast cancer in addition to surgery and/or radiation in post-menopausal women. (adooq.com)
Whereas emerging data on the efficacy of novel aromatase inhibitors in the adjuvant setting does not yet identify a group of patients for whom additional benefit is derived in terms of overall survival ( 4 , 5 ), both the ATAC and Intergroup Exemestane Study (IES) studies show a clear benefit in terms of disease-free survival. (aacrjournals.org)
shRNA inhibition of Nrf2 in LTLTCa (LTLTCa-Nrf2KD) cells reduced resistance and sensitized cells to aromatase inhibitor exemestane. (aacrjournals.org)
The combination of the aromatase inhibitor exemestane with with another breast cancer drug t. (bioportfolio.com)
Exemestane (EXE) is an aromatase inhibitor used for the prevention and treatment of estrogen receptor-positive breast cancer. (aspetjournals.org)

Since postmenopausal women have small and shrunken ovaries that produce low levels of estrogen, use of aromatase inhibitors may further prevent estrogen production and its stimulation of the tumour growth. (news-medical.net)
A new study claims a class of hormonal drugs called aromatase inhibitors may significantly reduce the risk of death among postmenopausal women with estrogen receptor-positive breast cancer - the most common form of the disease. (medicalnewstoday.com)
The risks and benefits of adjuvant aromatase inhibitors (AIs) should be weighed carefully, especially in postmenopausal women with early-stage, hormone-receptor positive breast cancer who also have coronary artery disease. (medscape.com)
This meta-analysis confirms that an aromatase inhibitor (AI) is not the best therapy for all postmenopausal women with hormone-receptor positive, early-stage, breast cancer. (medscape.com)
Aromatase inhibitors (AIs) have quickly become standard treatments for postmenopausal women with estrogen-receptor-positive breast cancer. (bcaction.org)
AIs inhibit the enzyme aromatase that converts testosterone to estrogen and that is used clinically in treatments of breast cancer in postmenopausal women. (wikipedia.org)
Aminoglutethimide is an NSAIs and therefore inhibits aromatase among other biosynthesis and is for example used to treat absence seizures, Cushing's syndrome, postmenopausal breast cancer and prostate cancer The first aromatase inhibitor that was discovered was aminoglutethimide, classified as first-generation AIs. (wikipedia.org)
Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. (springer.com)
Aromatase inhibitors (AIs) are a class of drugs used in the treatment of breast cancer in postmenopausal women and gynecomastia in men. (wikipedia.org)
Because some breast cancers respond to estrogen, lowering estrogen production at the site of the cancer (i.e. the adipose tissue of the breast) with aromatase inhibitors has been proven to be an effective treatment for hormone-sensitive breast cancer in postmenopausal women. (wikipedia.org)
BERLIN, April 18 -- In postmenopausal women with breast cancer, adjuvant treatment with aromatase inhibitors does not raise the risk for cardiovascular events, a researcher said. (medpagetoday.com)
Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women who have hormone-dependent breast cancer. (cancer.gov)
Aromatase is a cytochrome P-450-dependent enzyme system that catalyzes the conversion of androgens to estrogens in muscle and adipose tissue and is the major pathway of estrogen biosynthesis in postmenopausal women. (cancernetwork.com)
Aromatase inhibitors are only used to treat postmenopausal women (and some premenopausal women also getting ovarian suppression). (komen.org)
These results suggest that estrogens are mainly produced by aromatase in DCIS tissues, and aromatase inhibitors potently inhibit oestrogen actions in postmenopausal ER-positive DCIS through rapid deprivation of intratumoral estrogens. (nature.com)
These findings indicate the importance of oestrogen actions in DCIS, and aromatase inhibitors might be effective for postmenopausal women with ER-positive DCIS as well as invasive carcinoma. (nature.com)
disease because aromatase inhibitors are the standard hormonal therapy for postmenopausal women. (lbbc.org)
Important new data from two studies presented at the 27th Annual San Antonio Breast Cancer Symposium (SABCS) in the USA, suggest that 'Faslodex' (fulvestrant) is an effective and well tolerated treatment for postmenopausal women with advanced breast cancer who have experienced disease progression on aromatase inhibitor therapy. (presseportal.ch)
In this phase II trial, 77 postmenopausal women with advanced breast cancer whose disease progressed following treatment with an aromatase inhibitor and, at most, one additional hormonal agent, were assessed. (presseportal.ch)
To examine the correlation between estrogen suppression and aromatase inhibitors and BMI, Elizabeth Folkerd, PhD, of the Royal Marsden National Health Service Foundation Trust in London, and colleagues evaluated plasma estradiol and estrone sulfate levels with a highly-sensitive radioimmunoassay for 44 postmenopausal women with ER-positive breast cancer. (empr.com)
Vaginal gene expression in aromatase inhibitor-treated women was compared with postmenopausal control women treated with vaginal estrogen therapy. (diva-portal.org)
Background: Aromatase inhibitor (AI) treatment suppresses estrogen biosynthesis and causes genitourinary symptoms of menopause such as vaginal symptoms, ultimately affecting the quality of life for many postmenopausal women with breast cancer. (diva-portal.org)
HealthDay News - For postmenopausal women with breast cancer, extension of treatment with an aromatase inhibitor to 10 years is associated with improved outcomes, according to a study published online June 5 in the New England Journal of Medicine . (empr.com)
Each year, tens of thousands of postmenopausal women with hormone receptor-positive breast cancer, a type of cancer that is fueled by estrogen, are treated with aromatase inhibitors, which block the effects of estrogen to prevent a recurrence of the disease. (nyp.org)
Aromatase inhibitors became the choice of treatment for breast cancer in postmenopausal women because they block the synthesis of estrogens required by cancer cells to grow ( 10 ). (aacrjournals.org)
Third generation non-steroid aromatase inhibitors have shown important benefits in recent clinical trials with postmenopausal women. (chemaxon.com)
The use of aromatase inhibitors (AI) in the treatment of estrogen receptor (ER)-positive, postmenopausal breast cancer has proven efficacy. (aacrjournals.org)
Aromatase inhibitors (AI) are now the treatment of choice for estrogen receptor (ER)-positive postmenopausal patients with breast cancer. (aacrjournals.org)
Postmenopausal female breast cancer patients whose adjuvant treatment generally includes an aromatase inhibitor, or AI, often experience joint pain or stiffness known as AI-associated arthralgia. (unclineberger.org)
Aromatase inhibitors (AIs) are the most commonly used first-line endocrine treatment for postmenopausal women with estrogen receptor-positive breast cancer. (uwo.ca)

The enzyme aromatase works alongside NADPH (nicotinamide adenine dinucleotide phosphate) to convert male hormones or androgens to estrogens. (news-medical.net)
Aromatase inhibitors lower estrogen levels by preventing the enzyme aromatase - found in fat tissue - from changing other hormones into estrogen. (medicalnewstoday.com)
NSAIs binding is a reversible process where NSAIs binds to the aromatase enzyme through non-covalent interactions. (wikipedia.org)
When aromatase inhibitors (AIs) are used to treat breast cancer the main target is the aromatase enzyme which is responsible for the high estrogen level. (wikipedia.org)
Aromatase is an enzyme that belongs to the cytochrome P450 family located on chromosome 15. (wikipedia.org)
The active binding site of the aromatase enzyme is a subunit with a heme moiety (Fe2+). (wikipedia.org)
The binding of the NSAIs depends on the binding site of the aromatase as it has to fit into the substrate-binding site of the aromatase enzyme. (wikipedia.org)
Aromatase is the enzyme that catalyzes a key aromatization step in the synthesis of estrogen. (wikipedia.org)
Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization. (wikipedia.org)
The enzyme that is responsible for this conversion is aromatase, made primarily in fat and other tissue, especially in the breast. (cancersupportivecare.com)
A drug that prevents the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. (cancer.gov)
Within the past 10 years, the research team led by Dr. Bulun pioneered the molecular model that the aromatase enzyme, which produces estrogen, is present in the endometrial tissue of women with endometriosis. (prohealth.com)
AIs stop the production of estrogen by blocking the enzyme aromatase, which converts the hormone androgen into estrogen. (curetoday.com)
Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. (springer.com)
Aromatase is an enzyme that is required for the conversion of androgens or "male" hormones such as testosterone into estrogen. (sharedjourney.com)
Femara and Arimidex function as an enzyme inhibitor. (wdxcyber.com)
They prevent the enzyme aromatase from converting androgens (also known as the male hormones) into estrogen. (wdxcyber.com)
High levels of testosterone can mean higher levels of estrogen due to the conversion of testosterone to estrogen via the enzyme aromatase. (mrsupplement.com.au)
Which means that if there is an overabundance of testosterone around, the aromatase enzyme favours the production of estradiol. (mrsupplement.com.au)
The enzyme aromatase converts that hormone into estrogen. (lbbc.org)
Aromatase inhibitors interfere with the enzyme aromatase to decrease the female hormones in your body. (lbbc.org)
Femara and Arimidex work by blocking the enzyme aromatase from converting the androgens or "male" hormones into estrogen in both men and women. (gettingpregnant.co.uk)
Aromatase inhibitors can slow down the conversion of estrogen by binding to the aromatase enzyme and help balance the testosterone-to-estrogen ratio in men. (gettingpregnant.co.uk)
However I know that the AI in both of these is a class 1 suicide inhibitor which is supposed to be irreversible, but I was wondering, will my body slowly begin to produce the Aromatase enzyme again if I refrain from taking these supplements again, or is this completely permanent? (anabolicminds.com)
Aromatase, a rate-limiting enzyme catalyzing the conversion of androgen to estrogen, is overexpressed in human breast cancer tissue. (chemaxon.com)
Fadrozole is a nonsteroidal aromatase inhibitor exhibiting a very potent and selective inhibitory effect of the aromatase enzyme system in vivo and estrogen biosynthesis in vivo. (adooq.com)
It's one of a class of drugs called aromatase inhibitors and prevents the production of estrogen by binding to and shutting down an enzyme called aromatase. (algaecal.com)
Getting rid of excess body fat is the number one way to reduce your risk of hormone-positive breast cancer because your fat cells can produce estrogen from testosterone using an enzyme called aromatase - hence the use of aromatase inhibitors to block this process. (cancercompass.com)
An agent that blocks the function of the enzyme aromatase with antineoplastic activity. (rightdiagnosis.com)
Aromatase inhibitors belong to two classes: Type I steroidal drugs are androgen substrate analogues that bind competitively but irreversibly to the enzyme. (rightdiagnosis.com)
Type II nonsteroidal inhibitors fit into the substrate binding site and bind reversibly to the enzyme. (rightdiagnosis.com)
450 aromatase enzyme which depends blocking the biosynthesis of estrogen, and estrogen to stimulate breast cancer cell growth factors. (kitairu.net)

The purpose of this study is to determine how aromatase inhibitors (AIs) such as Arimidex, Aromasin or Femara affect a woman's oral health and oral health related quality of life. (clinicaltrials.gov)
In this video I wanted to discuss with you whether boron is safe for breast cancer survivors who are taking aromatase inhibitors such as Arimidex. (algaecal.com)
Arimidex inhibits estrogen synthesis by out- competing androgens' ability to bind with aromatase. (algaecal.com)
Arimidex and the other aromatase inhibitors are so effective at preventing the production of estrogen that if you are taking one of these drugs you will be producing virtually no estrogen. (algaecal.com)

Exemestan Aromasin Steroids Anti Estrogen Hormone Drugs For Breast Cancer Quick reviews of Aromasin aromatase inhibitors bodybuilding sterioids: 1. (xpandrally.com)

Howell A, Cuzick J (2005) Vascular effects of aromatase inhibitors: data from clinical trials. (springer.com)
Joint pain (arthralgia) and muscle pain (myalgia) are common side effects of aromatase inhibitors [ 85-87 ]. (komen.org)
Patients also need to consider the side effects of aromatase inhibitors and the cost of the drug. (facingourrisk.org)

A study suggests that smoking makes a class of hormonal therapy medicines, the aromatase inhibitors, much less effective. (breastcancer.org)
However, the aromatase inhibitors now provide an additional therapeutic approach for patients who remain candidates for hormonal therapy with disease progression in the face of antiestrogen therapy. (cancernetwork.com)
These new data therefore represent an important development that will be eagerly welcomed by the oncology community, since they suggest that women who have received prior non-steroidal aromatase inhibitor therapy now have an additional effective and well-tolerated hormonal therapy with which to fight their disease, extending the benefits of hormonal therapy and delaying the need for the more aggressive chemotherapy. (presseportal.ch)
A new study looks at whether extending one type of hormonal therapy, known as aromatase inhibitor therapy, to 10 years lowers recurrence rates even more for these women. (facingourrisk.org)

Too much of a good thing: polycythemia and aromatase inhibitors," AAP Capital Letters , abstract P3-680, 2010. (hindawi.com)
Anne Hudson Blaes, MD , of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07). (ascopost.com)

Aromatase inhibitor use has been shown to reduce the risk of breast cancer recurrence. (prweb.com)
Aromatase inhibitors aren't commonly used to reduce recurrence risk in premenopausal women. (breastcancer.org)
Still, when the researchers looked at just the 309 women older than age 50 diagnosed with estrogen-receptor-positive disease who were treated with an aromatase inhibitor after surgery, they found that smoking increased the risk of recurrence as well as the risk of dying from breast cancer. (breastcancer.org)
Smokers who were treated with aromatase inhibitors had a three times higher risk of recurrence of breast cancer compared with the non-smokers who got the same treatment," said Helena Jernström, associate professor at Lund University and lead author of the study. (breastcancer.org)
Loss of bone density and fractures are known risks of aromatase inhibitors in breast cancer survivors taking the drugs to reduce recurrence risk, Jane A. Cauley, DrPH, of the University of Pittsburgh, noted in an accompanying editorial. (medpagetoday.com)
Still, this treatment is not curative in advanced breast cancer, but many studies were then started to test aromatase inhibitors in early stage breast cancer in hopes that it could lower recurrence and mortality in early stage breast cancer. (cancersupportivecare.com)
For post-menopausal women diagnosed with hormone-receptor positive breast cancer tumors, aromatase inhibitors (AIs) are the standard adjuvant hormone treatment to prolong disease- free survival and time-to-recurrence. (clinicaltrials.gov)
Whether patients will benefit (lower risk of recurrence or new breast cancer in the other breast) if they stay on aromatase inhibitor therapy for 10 years rather than the standard 5 years. (facingourrisk.org)
The risk of disease recurrence and contralateral breast cancer was significantly lower among women who continued aromatase inhibitor for 10 years than among women who received placebo after the initial 5 years of aromatase-inhibitor therapy," the authors write. (empr.com)
Aromatase inhibitors have demonstrated efficacy in reducing the risk of breast cancer recurrence in hormone receptor-positive patients, but medication compliance can be limited by uncomfortable side effects, including musculoskeletal pain and dysfunction. (ascopost.com)
Updated analysis from the United Kingdom's POETIC trial found no evidence that perioperative aromatase inhibitor therapy slows or prevents time to recurrence of breast cancer. (ascopost.com)
The use of perioperative aromatase inhibitor therapy did not result in a reduction in time to recurrence. (ascopost.com)
We saw no evidence of improved clinical outcomes-ie, time to recurrence-with perioperative aromatase inhibitors," he said. (ascopost.com)
The use of aromatase inhibitors for 2 weeks before and 2 weeks after surgery, in early-stage breast cancer, did not reduce the time to recurrence in the large phase III POETIC trial. (ascopost.com)
Aromatase inhibitors are the most commonly used medications to prevent disease recurrence among post-menopausal women with early-stage, hormone receptor positive breast cancer. (healthcanal.com)

third generation aromatase inhibitors , used in the treatment of metastatic breast cancer and used as aid in the treatment of early breast cancer. (himfr.com)
In light of these limitations, the use of aromatase inhibitors to treat metastatic breast cancer in premenopausal patients should be limited to well-designed clinical trials. (cancernetwork.com)

Fifty percent of women taking aromatase inhibitors reported musculoskeletal pain, and up to 30% reported fatigue. (constantcontact.com)
About 46 percent of women taking aromatase inhibitors have joint pain and about 15 percent have muscle pain [ 85-87 ]. (komen.org)

Using testosterone as starting material, a new short synthesis of an aromatase inhibitor, 4-OHA, has been achieved through hydroboration/oxidation followed by a Swern type oxidation and epimerization. (mendeley.com)
Aromatase inhibitors block the conversion of testosterone to estrogen. (newswise.com)
Testosterone is naturally converted into estrogen by aromatase. (sharedjourney.com)
Aromatase inhibitors thus work by decreasing the amount of testosterone that is converted into estrogen, thus balancing hormone levels. (sharedjourney.com)
17alpha-methyl testosterone is a competitive inhibitor of aromatase activity in Jar choriocarcinoma cells and macrophage-like THP-1 cells in culture. (nih.gov)
However, 17alpha-methyl testosterone still could affect local estrogen formation by regulating aromatase expression or by inhibiting aromatase action. (nih.gov)
To evaluate the effect of 17alpha-methyl testosterone on the expression and activity of aromatase, we tested the choriocarcinoma Jar cell line, a cell line that express high levels of P450 aromatase, and the macrophage-like THP-1 cells, which express aromatase only after undergoing differentiation. (nih.gov)
We found that in both cell lines, 17alpha-methyl testosterone inhibits aromatase activity in a dose-related manner. (nih.gov)
17alpha-methyl testosterone does not have detectable effects on aromatase RNA and protein expression by Jar cells. (nih.gov)
Undifferentiated THP-1 cells had no aromatase activity and showed no effect of 17alpha-methyl testosterone, but differentiated THP-1 (macrophage-like) cells had a similar inhibition of aromatase activity by 17alpha-methyl testosterone to that seen in Jar cells. (nih.gov)
The Lineweaver-Burke plot shows 17alpha-methyl testosterone to be a competitive aromatase inhibitor. (nih.gov)
Our results show for the first time that 17alpha-methyl testosterone acts as an aromatase inhibitor. (nih.gov)
17alpha-methyl testosterone may, as a functional androgen and orally active steroidal inhibitor of endogenous estrogen production, also offer special possibilities for the prevention/treatment of hormone-sensitive cancers. (nih.gov)
And these include DHEA and testosterone and would normally be the targets of aromatase. (algaecal.com)
Aromatase inhibitors prevent the aromatisation of testosterone to estrogen, thus lowering circulating level of estrgoen in the body. (professionalmuscle.com)
When natural levels of hormones rise estrogen rises more rapidly than testosterone thus presenting the user with problems, even the use on an anti-e is sometimes not sufficient to blunt these effects, so an aromatase inhibitor is the better choice. (professionalmuscle.com)
Testosterone) and an aromatase inhibitor (e.g. (professionalmuscle.com)

Aromatase inhibitors are a new class of drugs that has been used to treat breast and ovarian cancer. (who.int)
We describe 4 patients in whom recurrent ovarian granulosa cell tumors were treated with an aromatase inhibitor, with promising results. (nih.gov)
Recent studies have showed aromatase inhibiters to be a safer alternative to the two primary drugs used for ovarian stimulation:clomiphene citrate (Clomid) and FSH. (gettingpregnant.co.uk)
Since the use of aromatase inhibitors for ovarian stimulation is relatively new, it is important to speak with your health care provider or doctor for more information on the side effects and risks associated with aromatase inhibitors. (gettingpregnant.co.uk)
And this means that taking boron is not going to have any negative effect on breast, prostate or ovarian cancer treatment if you are taking an aromatase inhibitor. (algaecal.com)
Aromatase inhibitors (AIs) may cause a rise in estrogen levels due to ovarian function recovery in women with clinical chemotherapy-induced ovarian failure (CIOF). (ovid.com)

However, among premenopausal who have these ER-positive tumours, the ovaries still produce estrogen at levels which mean aromatase inhibitors will not be able to inhibit tumour growth. (news-medical.net)
They inhibit aromatase specifically but not other biosynthesis like the first-generation, therefore many adverse effects are avoided. (wikipedia.org)
Both in vitro studies and clinical trials have suggested that use of the aromatase inhibitors (AIs), a class of anti-oestrogens, might inhibit ﬁbroid growth, thereby eliminating the need for surgery. (cochrane.org)
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones. (rightdiagnosis.com)

Compared with women who had not received hormone therapy, those who received aromatase inhibitors were 40% less likely to die from breast cancer in the 10 years after treatment initiation. (medicalnewstoday.com)
Newswise - Boston, MA- Aromatase inhibitors, when used for up to three years in combination with growth hormone, may effectively and safely help very short adolescent boys grow taller, new research suggests. (newswise.com)
Aromatase inhibitors (AIs) are most commonly used for breast cancer patients with hormone receptor positive disease. (hindawi.com)
This patient is only the second reported case of the use of an aromatase inhibitor in combination with growth hormone to optimize height in 11β-hydroxylase-deficient CAH. (aappublications.org)
Effective inhibitors of aromatase thus provide the potential for treatment of hormone-dependent breast cancer. (cancernetwork.com)
Aromatase inhibitors can be used as treatment after surgery for most post-menopausal women who have hormone-receptor positive tumours - which account for around 60 per cent of all breast cancers. (cancerresearchuk.org)
But these results further support the use of aromatase inhibitors as the first line treatment for post-menopausal women with hormone-sensitive breast cancer. (cancerresearchuk.org)
Aromatase inhibitors (AIs) are the major types of drugs to treat hormone-dependent breast cancer. (nih.gov)
By lowering the production of estrogen, aromatase inhibitors allow for the production of the luteinising hormone (LH) and follicle-stimulating hormone (FSH) , which play important roles in ovulation. (gettingpregnant.co.uk)
It is a type of hormone therapy called an aromatase inhibitor . (xpandrally.com)
Winer EP, Hudis C, Burstein HJ et al (2002) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. (springer.com)
Two-thirds of all breast cancers are hormone receptor-positive, and the treatment for it is to lower estrogen levels with aromatase inhibitors," said Dr. Dawn L. Hershman, leader of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center. (nyp.org)
In their study, true acupuncture was compared with sham acupuncture (needling at non-acupoints) or no acupuncture in 226 women with early-stage, hormone receptor-positive breast cancer who were being treated with aromatase inhibitors, all of whom had reported having significant joint pain on the Brief Pain Inventory-Short Form (BPI). (nyp.org)
Aromatase inhibitors are effective drugs that reduce or eliminate hormone-sensitive breast cancer. (aacrjournals.org)
Suppression of estrogen biosynthesis by aromatase inhibition is an effective approach for the treatment of hormone sensitive breast cancer. (chemaxon.com)
Aromatase inhibitors are the standard treatment for hormone responsive advanced breast cancer. (bioportfolio.com)

Clinically relevant musculoskeletal symptoms develop in women treated with aromatase inhibitors, leading to treatment discontinuation in a substantial percentage of these patients. (greenmedinfo.com)
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. (nih.gov)
I. To validate previously identified associations between 10 specific single nucleotide polymorphisms (single nucleotide polymorphisms [SNPs]) and discontinuation of treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS) among women with breast cancer. (bioportfolio.com)
I. To determine whether other SNPs in cytochrome P450 enzymes (CYP), glucuronosyltransferases (UGT), Vitamin D, serotonin and other receptors are associated with discontinuation of treatment due to the development of severe aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). (bioportfolio.com)
Musculoskeletal symptoms have been reported in 5% to 61% of patients on aromatase inhibitors, 1 with one study demonstrating that 20% of patients may discontinue the drug due to these side effects. (ascopost.com)
Diagnostic criteria for aromatase inhibitor-induced musculoskeletal symptoms have been published but not validated. (ascopost.com)
One suggested criterion is that the patient must have musculoskeletal symptoms that start while on the medication, improve within 2 weeks of stopping the medication, and restart when the aromatase inhibitor is resumed again. (ascopost.com)
As a more global approach, exercise has been studied to improve musculoskeletal symptoms, with a recent study looking at 150 minutes per week of moderate-intensity cardiovascular exercise and 2 days a week of resistance training, showing a statistically significant improvement in pain scores in patients on aromatase inhibitors. (ascopost.com)
Vitamin D levels may or may not be significant contributors to aromatase inhibitor-induced musculoskeletal symptoms, as studies have been conflicting. (ascopost.com)

Limited data suggest that these findings could be clinically relevant, but far more work is needed to determine whether modest differences in degree of estrogen suppression have an impact on the efficacy of the aromatase inhibitors," write the authors of an accompanying editorial. (empr.com)
These findings provide a rationale for the development of Nrf2 inhibitors to overcome resistance and increase efficacy of aromatase inhibitors. (aacrjournals.org)

But their study suggests another class of hormonal drugs - called aromatase inhibitors - may be more effective. (medicalnewstoday.com)
However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. (springer.com)
Aromatase inhibitors are the newest type of fertility drugs used in the infertility treatment of both men and women. (wdxcyber.com)
One of the major drawback of aromatase inhibitors, a class of drugs, commonly used in the management of estrogen receptor-positive (ER+) breast cancer is the debilitating joint pain. (rttnews.com)
30 Hours Description Lentaron, a.k.a. formestane, belongs to a class of drugs known as 2 (or second generation) aromatase inhibitors which are primarily used in. (himfr.com)
Aromatase inhibitors are a new group of drugs that are clinically useful in advanced breast cancer and Tam-resistant patients. (aacrjournals.org)
Some of these options include infertility treatments such as assisted reproduction techniques or fertility drugs like aromatase inhibitors. (gettingpregnant.co.uk)
Unlike other fertility drugs, aromatase inhibitors have not been linked to miscarriages . (gettingpregnant.co.uk)
These companies are able to obtain raw materials for aromatase inhibitors at a very cheap price, and this has driven the price down dramatically for these drugs. (ironmagazine.com)

Aromatase inhibitors are a class of hormonal agents that form part of the therapy for some types of breast cancer . (news-medical.net)
Venturini M, Del Mastro L (2006) Safety of adjuvant aromatase inhibitor therapy. (springer.com)
The authors adequately describe the design and rationale of other ongoing adjuvant therapy studies utilizing aromatase inhibitors. (cancernetwork.com)
The data from these two studies represent an important finding since they suggest that patients with advanced breast cancer who have progressed on aromatase inhibitor therapy have an additional effective and well tolerated hormonal treatment option at their disposal, which further delays the need to use chemotherapy. (presseportal.ch)
This data suggests that extending aromatase inhibitor therapy to 10 years instead of stopping it at 5 may improve patient outcomes. (facingourrisk.org)
Women who were on aromatase inhibitor therapy for 10 years did not have recurrences or develop new cancers in the other breast, although the difference between the 5-year and 10-year groups was relatively low. (facingourrisk.org)
Women should have a risk/benefit conversation with their healthcare providers to discuss if extending aromatase inhibitor therapy is right for them. (facingourrisk.org)
Women with node-positive breast cancer receive extended therapy, including an aromatase inhibitor (AI), for up to a total of 10 years of adjuvant endocrine treatment. (facingourrisk.org)
Should I extend aromatase inhibitor therapy to 10 years? (facingourrisk.org)
This is a trial of a 6-month extreme carbohydrate restricted diet (20 grams total carbs/day) via phone counseling with dietitian plus aromatase inhibitor therapy vs. 6-month control with aromatase inhibitor therapy alone. (facingourrisk.org)
So if you are strapped for cash you could just use the aromatase inhibitor post cycle with the usual clomid therapy. (professionalmuscle.com)
Several guidelines have been reported for bone-directed treatment in women with early breast cancer for averting fractures, particularly during aromatase inhibitor (AI) therapy. (menopause.org.au)
Goss PE, Ingle JN, Pritchard KI et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. (springer.com)
However, the study did show that tumor Ki67 levels after 2 weeks of perioperative aromatase inhibitor therapy are prognostic for outcomes and could guide the need for additional adjuvant treatment. (ascopost.com)
Experimental evidence and the small IMPACT trial 2 suggested that perioperative endocrine therapy may improve long-term disease-related outcome in patients undergoing primary surgery for estrogen receptor-positive breast cancer and that tumor Ki67 levels after 2 weeks of an aromatase inhibitor might predict outcomes better than pretreatment Ki67," Dr. Robertson said. (ascopost.com)
If Ki67 at baseline is high (≥ 10%), then Ki67 measurement after 2 weeks on aromatase inhibitor therapy can subdivide patients further. (ascopost.com)
A self-directed walking program shows promise in easing joint stiffness in older women who experienced these symptoms while taking aromatase inhibitor therapy for breast cancer, according to new findings presented by University of North Carolina School of Medicine researchers this week at the American College of Rheumatology Annual Scientific Meeting in San Diego, Calif. (unclineberger.org)

Explain to interested patients that this study found that aromatase inhibitors do not increase the risk for hypercholesterolemia or cardiovascular events. (medpagetoday.com)
The study also found that aromatase inhibitors produced higher clinical pregnancy rates and more frequent ovulation than Clomid -the number one form of treatment used to help women ovulate. (gettingpregnant.co.uk)

Ineffective Inhibition of Aromatase: A Cause for AI Resistance? (springer.com)
The expression of vaginal aromatase suggests that this could be the result of local and systemic inhibition of aromatase. (diva-portal.org)

Potent aromatase inhibitors, however, can reduce circulating estrogen levels to negligible amounts and almost completely prevent estrogen stimulation of cancer cell growth. (cancernetwork.com)
1] The most potent of the third-generation aromatase inhibitors seem capable of inhibiting aromatase activity both in peripheral sites as well as decreasing the intratumoral synthesis of estrogens. (cancernetwork.com)
These analyses have uncover a set of rules characteristic to active and inactive AIs as well as revealing the constituents giving rise to potent aromatase inhibition. (chemaxon.com)
3.The higher the number of " * " is, the more potent the inhibitor or activator is. (adooq.com)
Alpha-Naphthoflavone is a synthetic flavonoid, acts as a potent and competitive aromatase inhibitor with an IC50 and a Ki of 0.5 and 0.2 μM, respectively. (adooq.com)
Fadrozole hydrochloride is a potent, selective and nonsteroidal inhibitor of aromatase with an IC50 of 6.4 nM. (adooq.com)
In this study we have developed a new ligand-based strategy combining important pharmacophoric and structural features according to the postulated aromatase binding mode, useful for the virtual screening of new potent non-steroid inhibitors. (chemaxon.com)
New potent aromatase inhibitors were discovered to be active in the low nanomolar range, and a common binding mode was proposed. (chemaxon.com)
These results confirm the potential of our methodology for a fast in silico high-throughput screening of potent non-steroid aromatase inhibitors. (chemaxon.com)

Hot flashes and night sweats are common in women who take aromatase inhibitors [ 75 ]. (komen.org)
Vaginal dryness is common in women who take aromatase inhibitors [ 75 ]. (komen.org)
Women can take aromatase inhibitors orally and often experience few side effects. (gettingpregnant.co.uk)

The 2012 meeing of the Amercian Society of Clinical Oncologists included yet another study demonstrating the benefits of Vitamin D3 in breast cancer patients taking aromatase inhibitors. (constantcontact.com)
However, women should stop taking aromatase inhibitors upon becoming pregnant in order to prevent possible pregnancy complications and birth defects. (gettingpregnant.co.uk)
In this latest video, Lara talks about whether boron is safe for breast cancer survivors who are taking aromatase inhibitors. (algaecal.com)
PHILADELPHIA - Acupuncture can decrease the joint pain side effects often reported by breast cancer patients taking aromatase inhibitors (AIs), according to results of a new randomized trial conducted by a research team from the Abramson Cancer Center of the University of Pennsylvania. (healthcanal.com)

Breast cancer survivors who are prescribed an adjuvant aromatase inhibitor (AI) want ongoing communication with their oncology clinician about the potential for arthralgia and how these joint adverse effects can be managed through regular physical activity, a study published online ahead of print in the journal Supportive Care in Cancer has shown. (oncologynurseadvisor.com)

Safe Steroidal Aromatase Inhibitor Formestane (Lentaron) Powder Description: Formestane is classified as a selective irreversible steroidal aromatase inhibitor . (himfr.com)

Discontinuation and nonadherence were higher among breast cancer patients taking brand name aromatase inhibitors (BAIs) vs generic AIs (GAIs), according to a new study published October 27 in the JNCI: Journal of the National Cancer Institute. (prweb.com)
When Are Aromatase Inhibitors Wrong for Breast Cancer? (medscape.com)
The investigators behind a recent clinical trial testing acupuncture to treat joint pain caused by aromatase inhibitors used to treat breast cancer are spinning it as a positive study. (sciencebasedmedicine.org)
Aromatase inhibitors are generally not used to treat breast cancer in premenopausal women because, prior to menopause, the decrease in estrogen activates the hypothalamus and pituitary axis to increase gonadotropin secretion, which in turn stimulates the ovary to increase androgen production. (wikipedia.org)
Maura Dickler, M.D., of Memorial Sloan-Kettering Cancer Center in New York, commented that there is always a risk-benefit evaluation when choosing a treatment, and she had had some concern about cardiovascular risks with the aromatase inhibitors. (medpagetoday.com)
Adjuvant treatment with aromatase inhibitors in breast cancer result in higher rates of hot flushes, musculoskeletal complaints, osteoporosis and fractures. (greenmedinfo.com)
PHILADELPHIA - Use of electroacupuncture (EA) - a form of acupuncture where a small electric current is passed between pairs of acupuncture needles - produces significant improvements in fatigue, anxiety and depression in as little as eight weeks for early stage breast cancer patients experiencing joint pain related to the use of aromatase inhibitors (AIs) to treat breast cancer. (eurekalert.org)
Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. (springer.com)
Aromatase inhibitors were originally used in the treatment of breast cancer and prostate cancer, but now have proven effective at increasing the chances of getting pregnant. (wdxcyber.com)
A large clinical trial, which involved a total of 226 patients from 11 cancer centers, has found that acupuncture can significantly reduce the troublesome joint pain caused by the aromatase inhibitors. (rttnews.com)
Patients, dental professionals and medical oncologists will benefit from a greater understanding of the best oral care follow up practices of breast cancer survivors using aromatase inhibitors. (clinicaltrials.gov)
The article by Hamilton and Volm presents a timely and succinct review of the biology of aromatase and the current status of aromatase inhibitors as treatment for breast cancer. (cancernetwork.com)
In a multicenter study, researchers sought to determine if acupuncture effectively relieved aromatase inhibitor-related joint pain in patients with breast cancer. (oncologynurseadvisor.com)
No additional risk of colorectal cancer was noted among women treated with aromatase inhibitors (AIs) following a median follow-up of 2.4 and 2.9 years. (oncologynurseadvisor.com)
Patients with early-stage breast cancer treated with aromatase inhibitors often experience adverse events that lead to discontinuation. (oncologynurseadvisor.com)
Preoperative smoking is associated with increased risk for breast cancer events and distant metastasis in women treated with aromatase inhibitors (AIs). (oncologynurseadvisor.com)
Estrogen-dependent human breast cancer cells stably transfected with aromatase (MCF-7Ca) were used. (aacrjournals.org)
breast cancer, you may receive any of the three aromatase inhibitors as a first treatment after your stage IV diagnosis . (lbbc.org)
Aromatase inhibitors (AIs) have been used for the treatment of estrogen-dependent breast cancer in post-menopausal women by blocking the biosynthesis of estrogen. (chemaxon.com)
Because breast cancer survivors receiving aromatase inhibitors often experience adverse events of joint pain, stiffness, or achiness, researchers sought to assess survivors' knowledge regarding potential joint pain side effects and how both adverse events and their management through moderate physical activity could be discussed during routine visits with an oncology clinician. (oncologynurseadvisor.com)
Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer. (igi-global.com)
Aromatase is a multienzyme complex overexpressed in breast cancer and responsible for estrogen production. (igi-global.com)
Aromatase inhibitors and the treatment of breast cancer. (harvard.edu)
Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer? (aacrjournals.org)
Acupuncture decreased joint symptoms in women with early-stage breast cancer treated with aromatase inhibitors, according to a randomized, multicenter clinical trial led by researchers at NewYork-Presbyterian and Columbia University Irving Medical Center. (nyp.org)
Background The use of aromatase inhibitors (AIs), given after breast cancer, has been associated with a low bone mineral density (BMD) and as a risk factor for fragility fractures. (bmj.com)
RT-PCR and immunoblot assays showed that aromatase inhibitor-resistant breast cancer LTLTCa and AnaR cells express lower INrf2 and higher Nrf2 protein levels, as compared with drug-sensitive MCF-7Ca and AC1 cells, respectively. (aacrjournals.org)
Aromatase inhibitors are an effective first line of treatment for ERα-positive breast cancer that constitutes three-fourth of all types of breast cancers ( 7 ). (aacrjournals.org)
Breast cancer tissues have been shown to express aromatase and produce higher levels of estrogens than noncancerous cells ( 7 ). (aacrjournals.org)
A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer. (bioportfolio.com)

CGS 20267 is a new non-steroidal compound which potently inhibits aromatase in vitro (IC50 of 11.5 nM) and in vivo (ED50 of 1-3 μg/kg p.o. (adooq.com)

Aromatase inhibitors are useful in women who have already experienced the menopause and have ER-positive tumors. (news-medical.net)
Aromatase inhibitors remove only the tiny amount of estrogen that remains in the circulation of women after the menopause - but that's enough to have a substantial impact on a wide range of ER-positive tumors, despite their extraordinary differences at the molecular level. (medicalnewstoday.com)
The aromatase inhibitors can weaken bones and make women more likely to break a bone, though this is uncommon. (breastcancer.org)
These reports are dedicated to the women who generously took the time to respond to BCA's Aromatase Inhibitor Side Effects Survey and to everyone who seeks to make informed decisions about the care they receive. (bcaction.org)
This would counteract the effect of the aromatase inhibitor in premenopausal women, as total estrogen would increase. (wikipedia.org)
The study involved a prospective cohort of 290 women starting on aromatase inhibitors, who had baseline Vitamin D levels measured. (constantcontact.com)
This study demonstrates the potential of aromatase inhibitors to significantly and rapidly reduce disease severity and pain, offering women a new and more effective way of suppressing endometriosis with fewer side effects," explains Dr. Bulun. (prohealth.com)
We need to attack the root problem - the aromatase - in order to eliminate this cycle, halt the local production of estrogen and treat women with this disease. (prohealth.com)
Aromatase inhibitors like Femara may be used to stimulate ovulation in women. (sharedjourney.com)
Studies looking at the effectiveness of aromatase inhibitors have found that this type of fertility treatment boosts a higher rate of clinical pregnancies than Clomid, the popular fertility drug used by women. (wdxcyber.com)
Aromatase inhibitors like Femara trigger ovulation in women. (gettingpregnant.co.uk)
Aromatase inhibitors, unlike Clomid, did not affect estrogen receptors, and showed no negative effects on the endometrium (the inner lining of the uterus) or cervical mucus in women. (gettingpregnant.co.uk)
Women using aromatase inhibitor, like Femara, showed predictable multiple follicular responses in most cycles. (gettingpregnant.co.uk)
Vaginal tissue from aromatase inhibitor-treated women had low expression of genes involved in cell differentiation, proliferation, and cell adhesion, and associated with vaginal discomfort. (diva-portal.org)
In addition, aromatase protein staining was evident in the basal and the intermediate vaginal epithelium layers, and also in stromal cells with a slightly stronger staining intensity found in AI-treated women. (diva-portal.org)
Women who took the aromatase inhibitor for 10 years compared to 5 had no benefit in overall survival. (facingourrisk.org)
Women on 10 years of aromatase inhibitors experienced more side effects related to bone density and fractures. (facingourrisk.org)
This risk should be accounted for when managing aromatase inhibitor-treated women. (ices.on.ca)

The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). (springer.com)

is a member of the class of antiestrogens known as aromatase inhibitors . (chinacomputerparts.com)

A single-arm trial of duloxetine-up to 120 mg/d- showed clinically significant improvement in pain scores in patients on aromatase inhibitors. (ascopost.com)
Objectives To determine the predictors of fragility fractures in an observational cohort of female patients on aromatase inhibitors. (bmj.com)
Conclusions In the univariate analysis, many risk factors are associated with fractures within this cohort of female patients on aromatase inhibitors but both univariate analysis and multivariate analysis showed that lumbar spine BMD is a good predictor of fractures. (bmj.com)

More well-designed randomized controlled trials are needed to evaluate the effectiveness of aromatase inhibitor for treating uterine fibroids. (who.int)

Can aromatase inhibitors be used to prevent reccurrence of malignant mammary tumors in dogs? (oncolink.org)

The treatment with aromatase inhibitors worked significantly better in the non-smoking patients," she continued. (breastcancer.org)
the spine, hip, neck, and other sites also showed significantly worse bone loss with the aromatase inhibitor, despite the calcium and vitamin D supplementation used in the trial. (medpagetoday.com)
Spine, hip, neck, and other sites showed significantly worse bone loss with the aromatase inhibitor as well, despite the calcium and vitamin D supplementation used in the trial, the group reported online in the Lancet Oncology . (medpagetoday.com)
Although the mechanisms involved appeared to be similar for antiestrogens and aromatase inhibitors, the most significant effects occurred with Let, which were significantly greater than with E2W and consistent with marked effects of Let on tumor and cell growth. (aacrjournals.org)

Aromatase inhibitors can induce an arthralgia syndrome. (greenmedinfo.com)
Although the side effect profile of aromatase inhibitors is well known, including common side effects like arthralgia, bone pain, arthritis, hot flashes, and more serious problems like osteoporosis, we present a case of an uncommon side effect of these medications. (hindawi.com)
Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity [published online ahead of print January 12, 2016]. (oncologynurseadvisor.com)

When estrogen production is blocked by inhibition of the aromatase, it releases the hypothalamic-pituitary axis from the estrogenic negative feedback. (wikipedia.org)
By suppressing estrogen production, aromatase inhibitors encourage the production of LH and FSH, hormones that trigger ovulation. (sharedjourney.com)

As statins have a bone strengthening effect, combining a statin with an aromatase inhibitor could help prevent fractures and suspected cardiovascular risks, without potential of causing osteonecrosis of the jaw. (wikipedia.org)
Nabholtz JM, Gligorov J (2006) Cardiovascular safety profiles of aromatase inhibitors: a comparative review. (springer.com)
Pritchard KI, Abramson BL (2006) Cardiovascular health and aromatase inhibitors. (springer.com)

an aromatase inhibitor (AI, fadrozole) was administered to developing fishes from the 'first feeding' till the 100th day after hatching. (figshare.com)

Armigen is a powerful and novel aromatase inhibitor. (predatornutrition.com)

Anatomy3

Organisms2

Diseases12

Chemicals and Drugs37

Analytical, Diagnostic and Therapeutic Techniques and Equipment10

Psychiatry and Psychology2

Phenomena and Processes6

Health Care4

The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. (1/981)

Inhibitory effects of nitric oxide on the expression and activity of aromatase in human granulosa cells. (2/981)

Evidence of sex reversal in the gonads of chicken embryos after oestrogen treatment as detected by expression of lutropin receptor. (3/981)

Presence of an aromatase inhibitor, possibly heat shock protein 90, in dominant follicles of cattle. (4/981)

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. (5/981)

Estrogen-inducible, sex-specific expression of brain-derived neurotrophic factor mRNA in a forebrain song control nucleus of the juvenile zebra finch. (6/981)

Mitogenic and antioxidant mechanisms of estradiol action in preovulatory ovine follicles: relevance to luteal function. (7/981)

Gonadal stage-dependent effects of gonadal steroids on gonadotropin II secretion in the Atlantic croaker (Micropogonias undulatus). (8/981)

Aromatase Inhibitors

Triazoles

Nitriles

Fadrozole

Aromatase

Androstatrienes

Antineoplastic Agents, Hormonal

Tamoxifen

Breast Neoplasms

Androstenedione

Aminoglutethimide

Postmenopause

Neoplasms, Hormone-Dependent

Estrogens

Estrogen Antagonists

Androstadienes

Estradiol

Receptors, Estrogen

Estrogen Receptor Modulators

Testolactone

Chemotherapy, Adjuvant

Selective Estrogen Receptor Modulators

Testosterone

Estrone

Gynecomastia

Enzyme Inhibitors

Antineoplastic Agents

Receptors, Progesterone

Megestrol Acetate

Estrogen Receptor alpha

Ovary

Clinical Trials as Topic

Androgens

Pargyline

Drug Resistance, Neoplasm

Puberty, Precocious

Papio anubis

Hot Flashes

Arthralgia

Dihydrotestosterone

Endometriosis

Musculoskeletal Pain

Sex Differentiation

Follicle Stimulating Hormone

Ovariectomy

Clomiphene

Bone Density Conservation Agents

Treatment Outcome

Neoadjuvant Therapy

Gonads

Estrogen Receptor beta

Gonadotropins

Luteinizing Hormone

Receptor, erbB-2

Randomized Controlled Trials as Topic

Mammary Neoplasms, Experimental

Ovulation Induction

Placenta

Puberty, Delayed

Fibrous Dysplasia, Polyostotic

Uterine Diseases

Steroids

Diphosphonates

Double-Blind Method

Drug Administration Schedule

Bone Density

Cyprinidae

The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. (1/981)

Inhibitory effects of nitric oxide on the expression and activity of aromatase in human granulosa cells. (2/981)

Evidence of sex reversal in the gonads of chicken embryos after oestrogen treatment as detected by expression of lutropin receptor. (3/981)

Presence of an aromatase inhibitor, possibly heat shock protein 90, in dominant follicles of cattle. (4/981)

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. (5/981)

Estrogen-inducible, sex-specific expression of brain-derived neurotrophic factor mRNA in a forebrain song control nucleus of the juvenile zebra finch. (6/981)

Mitogenic and antioxidant mechanisms of estradiol action in preovulatory ovine follicles: relevance to luteal function. (7/981)

Gonadal stage-dependent effects of gonadal steroids on gonadotropin II secretion in the Atlantic croaker (Micropogonias undulatus). (8/981)

Letrozole in Treating Women With Primary Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy - Full Text...

Adjuvant Aromatase Inhibitor Therapy in Patients with Stage I Breast Cancer at a Regional Oncology Center in Israel:...

Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer - Full...

Adaptation of an Evidence-Based Arthritis Program for Breast Cancer Survivors on Aromatase Inhibitor Therapy Who Experience...

AB0260 The predictors of fragility fractures in patients on aromatase inhibitors: an observational study | Annals of the...

$AB0260 The predictors of fragility fractures in patients on aromatase inhibitors: an observational study | Annals of the...$ AB0260 The predictors of fragility fractures in patients on aromatase inhibitors: an observational study | Annals of the...

$Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor...$ Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor...